University of New Orleans

ScholarWorks@UNO
University of New Orleans Theses and
Dissertations

Dissertations and Theses

Spring 5-18-2012

Synthesis and Biological Evaluation of Rigid Analogues of
Methamphetamines
Andrea N. Forsyth
anforsyt@gmail.com

Follow this and additional works at: https://scholarworks.uno.edu/td
Part of the Medicinal-Pharmaceutical Chemistry Commons, and the Organic Chemistry Commons

Recommended Citation
Forsyth, Andrea N., "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines"
(2012). University of New Orleans Theses and Dissertations. 1436.
https://scholarworks.uno.edu/td/1436

This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO
with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an
authorized administrator of ScholarWorks@UNO. For more information, please contact scholarworks@uno.edu.

Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines

A Dissertation

Submitted to the Graduate Faculty of the
University of New Orleans
in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
in
Chemistry

by
Andréa Natassia Forsyth
B.S. University of New Orleans, 2006
May 2012

To Ronald L. Norris III and Satchiko, for being the best two things that have ever
happened to me. I am extremely thankful for Ron's constant love and support as
well as his atomic model-painting skills. Satchiko and her love of strange cheeses
and exotic head rubs have brightened many of my days.
To my family for their love and support.
To my friends for their encouragement and unique perspectives.

ii

Acknowledgement
The author would like to thank her advisor, Dr. Mark Trudell for his profound
patience and guidance throughout the years. She is extremely appreciative to have
been given the opportunity to do research in the area of medicinal/neurochemistry. She
is also thankful to her advisory board members, past and present: Dr. Guijun Wang, Dr.
Richard Cole, Dr. Anantha Sankaranarayanan, Dr. David Mobley and Dr. Branko Jursic.
She would also like to thank Dr. Sari Izenwasser and Mr. Dean Wade of the
University of Miami Miller School of Medicine for the biological analysis for this
dissertation.
She would also like to thank her group members, past and present for their
thoughts and encouragement through the years: Dr. Shaine Cararas, Dr. Xiaobo Gu, Dr.
Lei Miao, Dr. Hong Shu, Dr. April Noble-Brooks, Abha Verma-Goyal, Amber Thaxton,
Alexander Sherwood, Kiran Thota, Maria Lindsay, Maria Zacharioudaki and Yiressy
Izaguire.
She would also like to extend a keen appreciation to the Louisiana Board of
Regents and the National Institute for Drug Abuse for their financial support of this
research.

iii

TABLE OF CONTENTS
LIST OF SCHEMES ..............................................................................................v
LIST OF FIGURES...............................................................................................vi
LIST OF TABLES ...............................................................................................vii
ABSTRACT ......................................................................................................viii
Introduction ........................................................................................................1
Addiction ...........................................................................................................1
Monoamine Neurotransmitters ..........................................................................3
Amphetamines ..................................................................................................5
Therapeutic Targets ..........................................................................................7
Azetidine Ring System ....................................................................................10
Synthetic Strategy ...........................................................................................14
Results and Discussion ....................................................................................15
Conclusion.........................................................................................................20
Experimental Section ........................................................................................30
References .........................................................................................................58
Appendix ............................................................................................................64
Vita......................................................................................................................80

iv

LIST OF SCHEMES
Scheme 1 ............................................................................................................42
Scheme 2 ............................................................................................................42
Scheme 3 ............................................................................................................43
Scheme 4 ............................................................................................................44
Scheme 5 ........................................................................................................... 45
Scheme 6 ...........................................................................................................46
Scheme 7 ........................................................................................................... 47
Scheme 8 ........................................................................................................... 49
Scheme 9 ........................................................................................................... 49
Scheme 10 ......................................................................................................... 50
Scheme 11 ......................................................................................................... 51
Scheme 12 ......................................................................................................... 52
Scheme 13 ......................................................................................................... 54
Scheme 14 ......................................................................................................... 56
Scheme 15 ......................................................................................................... 57
Scheme 16 ......................................................................................................... 58

v

LIST OF FIGURES
Figure 1 .................................................................................................................4
Figure 2 .............................................................................................................. 12
Figure 3 ...............................................................................................................32
Figure 4 ...............................................................................................................35
Figure 5 ...............................................................................................................37
Figure 6 ...............................................................................................................37
Figure 7 ...............................................................................................................38

vi

LIST OF TABLES
Table 1 ................................................................................................................13
Table 2 ............................................................................................................... 16
Table 3 ............................................................................................................... 39
Table 4 ............................................................................................................... 41
Table 5 ............................................................................................................... 54
Table 6 ............................................................................................................... 56
Table 7 ............................................................................................................... 60
Table 8 ............................................................................................................... 62

vii

ABSTRACT
A series of rigid azetidenyl-based methamphetamine analogs were synthesized from
commercially available N-Boc-azetidinone. The benzylideneazetidine analogs were prepared via
a Wittig olefination via the ylides generated from the corresponding triphenylphosphonium
benzylhalide salts. The substituted benzylazetidine analogs were synthesized from the
corresponding benzylideneazetidienes via hydrogention over palladium and platinum catalysts.
The benzylideneazetidine and benzyliazetidine analogs were evaluated at monoamine
transporters as a part of preliminary structure-activity study for the development of novel
monoamine transporter ligands. The binding affinities of the azetidine analogs were determined
at dopamine (DAT) and serotonin (SERT) transporters in rat brain tissue preparations. The
preliminary in vitro binding studies revealed that the rigid scaffold of the azetidine ring system
was an effective substitution for the 2-aminopropyl group of methamphetamine and led to
compounds with nanomolar binding affinity at dopamine and serotonin. In general, the
benzylideneazetidine analogs were more potent than the corresponding benzylazetidine
analogs. In addition, the azetidine analogs were more selective for the serotonin transporter
than the dopamine transporter. The 3-(3,4-dichlorobenzylidene)azetidine (24m) was the most
potent analog of the series with Ki values of 139 nM for SERT and 531 nM for DAT (DAT/SERT
= 3.8).

Key words: dopamine, serotonin, norepinephrine, methamphetamine, amphetamine, azetidine,
psychostimulants
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INTRODUCTION
Psychoactive substances are substances that when taken, alter perception, mood
and/or consciousness. Humanity has a lengthy history of using psychoactive
substances for reasons ranging from spiritual to recreational. In today's world, most of
these substances are prohibited without proper medical oversight. Despite the legal
prohibition, illicit drugs are a global phenomenon and addiction appears to be pandemic.
One group of particular psychoactive substances are amphetamines. The most
recent SAMHSA reports show that while the use of amphetamine type stimulants (ATS)
appears to be declining in the US, the UN has recently reported that globally, ATS use
is increasing.1,2 These stimulants are easily synthesized, cheap, readily available and
highly addictive. Unlike some other psychostimulants, methamphetamine is known
possess neuro-toxicity.3 Problems stemming from amphetamine addiction range from
poor individual health, criminal activity and environmental hazards stemming from meth
labs. As of this writing, there are no good pharmacotherapies for those seeking
treatment.
Addiction
Drug addiction is a cyclical condition typified by two major characteristics: the
compulsion to take the drug and the user's loss of intake control.4 The DSM-IV breaks
the addiction cycle down further into three stages: preoccupation/anticipation, bingeintoxication and withdrawal-negative effect.5 Between these stages the user may take
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larger than intended amounts of the substance and develop tolerance which leads to
further health complications.
Statistically, many more people try psychostimulants than actually become addicted
to them. Research has shown that there are both genetic and environmental factors
which influence our ability to become addicted and subsequently, our likelihood for
relapse. Studies focusing on families and twins have shown genetic influence estimates
ranging from 30-60%.6 Differences in the dopaminergic network have also been linked
to impulsivity and drug craving.6,7 The underlying neurochemical bases for certain
psychiatric conditions (e.g. schizophrenia, bipolar, depression, etc) is often temporarily
ameliorated by the effects of psychostimulants, however the user also runs a significant
risk of developing dependence due to habitual self-medication.
The chronic exposure to drugs of abuse induces molecular neuroadaptations that
occur throughout the nervous system as well as in the dopamine receptors in the
nucleus accumbens.4 These gradual changes in the neural substrate have given rise to
the theory of addiction as a disease of gradual neural changes that are driven by the
body's need to maintain homeostasis. As exposure to the drug persists, other
physiological systems are recruited along with the neuroadaptations causing the
organism to set new 'normal' parameters termed allostasis.4
The prolonged exposure to psychoactive substances alters neuropathways and
substrates to create a new allostatic physiological state which can have many adverse
effects to mental and physical health. Since any given physiological parameter (e.g.
blood pressure) can be controlled by numerous but mutually interacting signals; altering
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any of these can lead to a multitude of changes in various feedback loops, further
complicating the system's ability to regulate. Given that many psychostimulants act on
one or more neuroreceptors, this increasingly complicates the homeostatic picture.
Since levels of neurotransmitters and other variables have been significantly altered,
the system goes into what has been termed an allostatic state. While an individual is in
this state, their ability to cope with further stress is impaired as the margins for coping
have decreased due to their altered physiological state.4 The constant stress of the
system and its impaired ability to relax increase the odds of breakdown and illness. The
term "allostatic load" is used to describe this physiological tab the body runs while
performing under such stress. This running tab leads to the quickened deterioration of
tissues of the brain, skin and/or vital organs. Other side effects are due to the impaired
judgment of the user, such as needle-sharing, which can easily lead to the spread of
disease. Users of psychoactive substances often show heightened emotional states and
compulsive urges to use or get drugs, making them potential hazards to their
communities.
Amphetamine History
The story of amphetamines begins with over 5,000 years ago in China, where
herbalists and healers used Ephedra as a circulatory stimulant, diaphoretic, antipyretic
and respiratory aid. Other species of Ephedra were utilized for medicinal value in
Greece, Russia, India and the Americas.10 Its value as an appetite suppressant,
respiratory aid and (in the Americas) venereal disease treatment, made it an extremely
popular medicine. Its dominance as a respiratory aid went virtually without competition
for many years. Japanese chemists began to study the medicinal quality of the plant in
3

the 19th century. In 1885, Nagayoshi Nagai isolated the alkaloids responsible for
activity, l-ephedrine ( 1, 40-90% of the total alkaloids), d-pseudoephedrine (2). Two
other notable alkaloids were isolated, norephedrine (3) and norpseudoephedrine (4),
which have limited therapeutic use. On the other side of the world in 1887,
amphetamine (5) was synthesized in Germany. In 1893, Nagai went on to synthesize a
derivative of ephedrine, methamphetamine (6).
Figure 1: Ephedrine alkaloids and derivatives

In 1887 a colleague of Nagai named Miura performed various animal studies on lephedrine to demonstrate any pharmaceutical qualities. His findings suggested that the
drug was "too toxic" for use in the whole animal, but it could be safely used to safely
(reversibly) dilate the pupils - a stark contrast from atropine (a drug that was commonly
used at the time, whose effects may last upwards of a week).11 The epinephrine-like
qualities of the ephedra alkaloids were described by several other chemists, but it was
not until the 1924 paper by Chen and Schmidt that Western science began to examine
ephedra.
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Their subsequent discoveries of ephedra's side effects - specifically the capillaryconstriction effect offered a unique therapeutic for a common problem - nasal
decongestion.12 It was introduced into the market in 1926 by Lily and became very
popular, especially among sufferers of asthma.11,12 Since the active ingredients are
readily available from nature, many sought to control the import of the plant. The import
control coupled with the fact that extracts of ephedra contained a significant portion of dpseudoephedrine and the 1937 invasion of China by the Japanese (which led to
ephedra shortages) spurred a surge of research into alternatives.11 It is this search for
alternatives that ultimately led to the mass production and use of amphetamines.
During the 1920s, Gordon Alles was one of those researchers seeking to capitalize
on ephedra's anti-allergy abilities. His research focused in on the sulfate salt of
phenylisopropylamine (amphetamine) which he tested on animals and observed it had
similar effects and was not "terribly toxic."12 In 1929, he tested the compound on
himself and observed the following: "a feeling of well-being, palpitation, and eventually a
sleepless night ... in which his mind seemed to race from one subject to another."12
However, it was amphetamine's usefulness as a bronchodilator and decongestant that
eventually led to it overtaking ephedra and found Alles with a patent on amphetamine.13
Smith, Kline and French filed a separate patent on an amphetamine inhaler called
"Benzedrine sulfate" in 1933 which was little more than amphetamine in a small tube.12
A year later, Alles would transfer his patent to Smith, Kline and French who further
developed the amphetamine salts as drugs. In 1937, Smith, Kline and French received
the approval from the American Medical Association to advertize benzedrine sulfate for
conditions ranging from narcolepsy, post-encephalitic Parkinsonism (a condition caused
5

virally that leads to the deterioration of the cells of the substantia nigra and Parkinson'slike symptoms) and minor depression.13 The popularity of benzedrine (amphetamine)
eventually led to the marketing and over use of specific stereoisomers and
methamphetamine (methedrine).
Global Usage and Addiction of Amphetamines
The would-be "golden age" of American meth- amphetamine use could be thought of
as a period from the late 1920s to around 1970.12,13,14 Even before the onset of World
War II, the drugs had gained widespread attraction for their ability to increase the
activity and enhance the mood of the user as well as the drugs' ability to enhance
weight loss.13 In 1939 benzedrine sulfate (amphetamine sulfate) received FDA approval
for the treatment of obesity.13 Compared to other methods of treating depression (such
as the popular frontal lobotomy), amphetamines allowed for a much less intrusive
treatment of the condition.13
The ability of meth- amphetamine to keep people alert for days on end was exploited
during World War II.12-15 The Allied and Axis sides both rationed out benzedrine
(amphetamine) to soldiers to help alleviate fatigue and improve mood and
endurance.14,15 After the war, a paper by Monroe and Drell suggested a link in military
service and "agitated hallucinating patients" whom were addicted to "eating the contents
of benzedrine inhalers" (~250 mg of amphetamine).13,16 Both physicians were stationed
at a military prison and had noted that only 11% of the addicted patients had used a
form of amphetamine before their military career.13,16 A significant amount (27%) had
been exposed to amphetamine while in the military, usually by an officer in the form of a
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pill compared with 5% of non-addicted inmates.13,16 It is estimated that around 16 million
Americans had been exposed to amphetamine (in the form of benzedrine sulfate) during
their service in the military.13 Since the benzedrine inhaler was readily available without
a prescription, this had the effect of a massive "word of mouth" campaign amphetamine
exposure and potential addiction.
By the end of the war in 1945, over 500,000 civilians in the US were using
amphetamine for everything from weight loss to depression.12-17 Stockpiles of
amphetamine (and methamphetamine) became more readily available in the years
following the war, and misuse was becoming more common.12-17 As legal usage
increased, so did the illicit trade and addiction of amphetamines, though it would take
years before the addictive properties of the drugs were recognized. The black market of
amphetamines provided a product for anyone looking to improve his performance either
in studying or athletically, or looking to stay awake during long-hauls.
During the 1950s, the first references to intravenous amphetamine usage appear,
but was not a widespread practice until the 1960s.14 In the early '60s the government
began to crackdown on pharmacies which sold injectable amphetamines. This
crackdown led to illicit production going underground and giving rise to the now
infamous home laboratories. By the 1970s, the usage of amphetamines declined
considerably thanks to the DEA crackdowns and FDA scheduling of the drug.14,18 In the
1990s, the DEA began a crackdown of cocaine which began a resurgence in
amphetamines thanks to traffickers bringing the drugs from Mexico.
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Outside of the US, amphetamine usage has been prevalent since the 1950s and
1960s.2,12-15,17 Japan has had two amphetamine addiction epidemics. During World War
II, the Japanese also rationed out methamphetamine to their troops as well as their
factory workers to increase out-put. During and after the war, supplies of
methamphetamine became freely available to the public.2,17,19 At one point, 5% of the
population of Japan was addicted to meth- amphetamines, around one-tenth of which
were estimated to have experienced methamphetamine-induced psychotic symptoms.19
This led to intervention by the government in 1951 when the stimulant control act was
passed. A resurgence of amphetamine addiction occurred again in the 1980s and is
ongoing. This second wave of amphetamines are either made in clandestine labs or are
trafficked in from abroad. Given the problematic history of amphetamines in Japan, in
2008 a decision was made to ban all amphetamines - including pharmaceutical
preparations (Adderall).2,20 Travelers now bringing such medications into the country are
arrested on the spot.20
In eastern Asia, methamphetamine abuse has taken over as the most commonly
abused drug, surpassing heroin, cocaine, opium and cannabis. While many of these
drugs are manufactured in places such as China, Myanmar or the Philippines,
methamphetamine seized in places such as Japan and South Korea often can be
traced to west Africa.2 Western and southern Asia are experiencing a similar situation
as seizures of amphetamines are increasing and countries which one imported the
stimulants are now exporters (Iran).2,22 This may change as countries around the world
are drafting much harsher legislation and are receiving advanced training in the
detection and prevention of drug production and distribution.21,23
8

Europe's usage levels of amphetamines appears to be steady.2 Seizures in countries
such as Germany are increasing, but the overall usage throughout the continent
remains consistent. Unlike the global trend, amphetamine is much more popular than
methamphetamine. Amphetamine is usually produced in Poland or the Netherlands,
whereas the Czech Republic is the main manufacturer of methamphetamine.2,23
Detailed knowledge of the production and use of amphetamine-type stimulants in
Africa is lacking.2 There are three major known sites of production within the continent,
Egypt, Nigeria and South Africa. Data about lifetime use is limited given the perennially
stretched resources of most governments in the region. It is known that amphetamine
production has occurred throughout Egypt since before 2000 but its role as a regional
supplier is not well understood. A tanker of methamphetamine that had its origins in
Egypt was recently seized in Saudi Arabia.2 Recent reports from Nigeria present a
potential epicenter both as a regional manufacturer and a global distributer.
Methamphetamine from Nigeria has been seized by Japanese authorities in increasing
amounts since 2009.2 Similarly, South Africa has been implicated as a significant
supplier of methamphetamine to Australia. While the country continues to strengthen
legislation controlling the import of important precursors, increasing amounts of
amphetamines are being seized.23
In central and South America, there appears to be an on-going exchange with
Europe of cocaine for amphetamines. While few labs have been raided, production is
known to be on-going in places such as Argentina and Brazil. Use of amphetamines is
highest in countries such as El Salvador (3.3%), Belize (1.4%) and Costa Rica (1.3%).2
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The current concern is now focused on the increase of production given that countries
in North America have tightened controls on precursors.
As of this writing, amphetamine type stimulants are the second most commonly
abused drug in the world (behind cannabis) - far outstripping heroin and cocaine.2
Smuggling is a major issue in many countries, and given that the origins of many seized
dosages are from unstable or authoritarian regimes, there are legitimate security
questions (fighting wars, sponsoring terrorism, etc). The physiological and psychological
toll amphetamines take on the user and his community, these drugs present a global
sociological hazard. In 1971, the DEA scheduled methamphetamine and amphetamine
as Schedule II substances.24
Amphetamine Mode of Action Overview
Amphetamines can be ingested orally, intravenously or by smoking. Users describe
different experiences depending on how the drug is ingested; smoking and injection
leads to an intense rush that lasts only a few minutes, while snorting and oral routes
lead to a less intense high. In many countries, amphetamines have become the number
one illicit injecting drug. The half-life of the drug depends on the method of ingestion,
where oral administration has an elimination half-life of 10.1 hours and intravenous
administration has a half-life of 12.2 hours.19,25
Peak plasma concentrations also vary by method of ingestion; injection leads very
quickly to peak concentrations, smoking meth- amphetamines requires a few minutes
and oral intake gives a peak plasma concentration after around 3 hours.19,25 The high
attributed to amphetamine usage can dissipate before the blood concentrations of the
10

drug fall substantially, leading many users to ingest very high dosages of the substance
and further fueling tolerance.26 Typical of stimulant users, amphetamine type stimulant
users tend to follow a "binge and crash"-type pattern of use where users will be awake
for days taking the drug before finally 'crashing' (often sleeping for several days).26
Once ingested, amphetamines readily cross the blood brain barrier. Once in the
central nervous system, the drugs are extremely active with the monoaminergic
(especially dopaminergic) transporters. Generally, the extracellular amphetamines bind
to the uptake carriers where they are then transported into the cell. Once in the cytosol,
amphetamines are able to enter the neurotransmitter storage vesicles by bonding to the
vesicular monoamine transporter (VMAT-2) which begins to exchange the
neurotransmitter (e.g. dopamine) for the amphetamine.27 The loss of the reductive
influence of the vesicles results in cytosolic oxidative stress which may also play a role
in the neurotoxicity typical of methamphetamine.17 In the case of dopamine, as the
concentration of it increases in the cytosol, the dopamine transporter bonds to the
cytosolic dopamine and transports it from the terminal into the synaptic space.
There has also been some consideration of a 'weak base model' which states that
amphetamines can redistribute catecholamines from synaptic vesicles by collapsing the
vesicle proton gradient.17 The proton gradient usually provides the free energy required
for catechol accumulation, with this gradient disestablished they simply enter the
synapse. This theory also states that even non-stimulant weak bases should also work
in this manner.17
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There is a great deal of structural similarity between amphetamine (5) and the
endogenous ligand β-phenylethylamine (7) (Figure 2). Both molecules act as releasers
of various monoamines (Table 1). The fact that the monoaminergic neurotransmitters
may serve as releasers may indicate a feedback mechanism as of yet not understood.
Intoxication from the substance is a result of the 'overflow' of these monoamines.
Symptoms due to amphetamine intoxication results in tachycardia, hypertension,
pupillary dilation, profuse sweating, rapid breathing, peripheral hyperthermia,
hyperpyrexia, light sensitivity, anxiety, headaches, paranoia, delusions, and
hallucinations.19,25 Users also experience dry mouth, bruxism (teeth grinding - a
contributing factor to "meth mouth"), the sensation of "bugs" crawling on the skin
(delusional parasitosis) and sores; which can be attributed to the overabundance of
norepinephrine.28,29 Long-term effects of meth- amphetamine usage also include
changes in neuronal structures as well as transporter levels which have been shown to
persist even after extended periods of abstinence.30,31,32
Figure 2: SAR Comparison of Amphetamine to β-Phenethylamine

Figure modeled after Palmer.33
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Table 1: Comparison of DAT, SERT and NET Releasing Activity of
Neurotransmitters and Amphetamines (EC50)
Compound

Name

8

DAT (nM)

SERT (nM)

NET (nM)

Dopamine

86.9

Inhibitor

66.2

9

Norepinephrine

869

Inactive

164

10

Serotonin

1960

44.4

Inhibitor

11

Tyramine

119

2775

40.6

39.5

Inactive

10.9

7

Structure

β-Phenethylamine

12

R-(-)-amphetamine

27.7

-

9.5

13

S-(+)-amphetamine

8.7

-

10.2

14

R-(-)-methamphetamine

416

-

28.5

15

S-(+)-methamphetamine

24.5

-

12.3

Adapted from Blough.34
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The alpha methyl group on meth- amphetamine prevents ready metabolism of these
compounds and in effect allows them to inhibit monoamine oxidase (MAO).35 Inhibiting
MAO prevents the metabolism of neurotransmitters, increasing the number of
neurotransmitter present in the cytosol and allowing them to interact with other
molecules within the cell. In the dopaminergic cells, this leads to an amphetamineinduced but dopamine-dependent neurotoxicity where the nerve terminals "burn out"
and leave the body of the neuron intact.36 The neuronal toxicity of the dopaminergic
pathways exhibited by amphetamines (especially methamphetamine) is usually
observed after long term, high dose use.36,37 Sustained high dosages of amphetamines
in experimental animals produces a persistent depletion of dopamine associated with
terminal degeneration as well as neuronal chromatolysis in several areas of the brain
(brain stem, cortex and striatum).17 Compared to continuous high dosage of another
psychostimulant (cocaine), no terminal degeneration in the frontal cortex or striatum
was observed.17 The toxicity of methamphetamine has been shown to be inhibited by
dopamine synthesis inhibitor alpha-methyl-p-tyrosine; dopamine/NDA-receptor
antagonists an dopamine or serotonin re-uptake inhibitors (which protect their specific
neurons). There is also a link between the hyperthermia induced by amphetamines, the
social interactions of its users and potential neurotoxicity.38
Amphetamines are neither quickly removed nor metabolized by the body. Both drugs
and their metabolites are cleared primarily through the urine (Table 2).39,40 In the case of
orally ingested amphetamine, a study found that over a four day period, 90% of the
initial dose was excreted.39 Of this, 60-65% was retrieved on the first day, with 30% of
the mixture being the unchanged drug, 21% benzoic acid (16) and 3%
14

hydroxyamphetamine (17).39 In the case of methamphetamine, the clearance pattern is
similar, with 90% being recovered over a 4 day period. Unlike amphetamine,
approximately 50% of the dose recovered was the unchanged drug (22% of which was
excreted in the urine on day one).40 The other metabolites of methamphetamine are 4hydroxymethamphetamine (18) (15% recovered) and several minor metabolites:
hippuric acid (19), norephedrine, 4-hydroxyamphetamine (17) and 4hydroxynorephedrine (20).40 The slow clearance and low-metabolism of these drugs
allows them to remain active physiologically much longer than the initial high. As a
comparison, the half-life of cocaine is about 40 minutes and 80-90% of injected cocaine
(most bioavailable method of ingestion) is rapidly metabolized.41 Only 1-5% of cocaine
is excreted as the unchanged drug within 6 hours of use.
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Table 2: Metabolites of Amphetamines39,40
Compound

Name

Structure

5

Amphetamine

16

Benzoic acid

17

Hydroxyamphetamine

6

Methamphetamine

18

4-hydroxymethamphetamine

19

Hippuric acid

3

Norephedrine

17

4-hydroxyamphetamine

20

4-hydroxynorephedrine

*

Amount (%)
>30%

*

21%

*

3%

**

50%

**

15%

**

Minor

**

Minor

**

Minor

**

Minor

*

- Metabolites of amphetamine. **- Metabolites of methamphetamine
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It should be noted that while the above lists the physiological effects of long term
meth/amphetamine use, low dosages under a physician's care can be safe and effective
for some neurological conditions. One of the most common treatments for ADD/ADHD
and narcolepsy is Adderall or dexedrine which are amphetamine salts. These drugs can
both increase attention as well as aid in wakefulness that is desired by both conditions,
improving quality of life significantly for patients. Blood concentrations of these drugs
usually are in the range of 0.02-0.05 mg/L, compared to recreational users whose
concentrations range from 0.01-2.5 mg/L (concentrations above which may be toxic).25
Monoamines, Their Receptors and Transporters
While the roles of the monoamines and their receptors are discussed at length in the
following, we would like to take the opportunity to discuss some of the shared
characteristics of their transporters. Monoamine transporters belong to a super-family of
facilitated transporters, specifically the 12 transmembrane domain neurotransmitter:
sodium symporter family (NSS).42-44 These transporters are able to translocate their
substrates across the membrane bilayer by exploiting an ion gradient, which is driven by
the naturally occurring sodium ion gradient.44 This allows them to operate in two
directions, depending on concentration gradients/net driving force.42,43 Cotransport of
chloride ion is also required for the following transporters, with additional (and particular)
needs for the dopamine and serotonin transporters.
These transporters also act similarly by releasing their neurotransmitter (serotonin,
norepinephrine and dopamine) when binding amphetamines.43 This ability of
amphetamines to cause efflux while they are being transported into the cell is not
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adequately explained by the alternate access model. The facilitated exchange diffusion
model is similarly inadequate as it fails to explain why the transporter would release
neurotransmitter instead of meth- amphetamine. It has since been suggested that
monoaminergic transporters operate as counter-transporters in the presence of
amphetamines.43 Release of neurotransmitter and uptake of amphetamines occurs
through separate by coupled moieties which are also coupled in changes of the ionic
gradients.43 A second stimulus by a protein kinase C isoform primes the inward facing
conformation for outward transport, which accounts for the influx/efflux behavior.43
Norepinephrine
As a neurotransmitter, norepinephrine is principally a excitatory. It is ultimately
derived from vesicular dopamine through the action of dopamine β-hydroxylase. Almost
every neural region receives input from these neurons. The cell bodies are located in
seven regions of the pons, the medulla and one region of the thalamus.45 The locus
coeruleus-noradrenergic system supplies norepinephrine throughout the central
nervous system through a far-reaching series of efferent projections.46 Unlike dopamine,
or serotonin; the release of norepinephrine does not occur at synaptic buttons, but
rather along axonal varicosities (beadlike swellings along the branches of the
neuron).45

Norepinephrine Receptors
Receptors are sensitive to both epinephrine (secreted by the adrenal medulla) and
norepinephrine. Two major types of receptors have been described for norepinephrine;
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the α- and β- types of which there are a total of five subtypes (α1, α2; β1, β2, and β3).45
All of these subtypes are found outside of the CNS, and so far the β3 receptor appears
to be exclusively located outside of the CNS (predominantly in adipose tissue). All of
these subtypes are able to produce excitatory and inhibitory neural effects, although
behavioral effects are almost exclusively excitatory. In the brain, almost all
autoreceptors appear to be of the α2 subtype. In the brain, α1 receptors are able to
produce slow, depolarizing effects on the post-synaptic cell membrane (excitatory).
Alternatively, the α2 receptor produces a slow hyperpolarization (inhibitory). Both β1 and
β2 neuro-receptors increase the response of post-synaptic neurons to excitatory inputs
which likely leads to the increased alertness experienced by subjects.45
Norepinephrine is known to modulate serotonin and dopamine release, especially in
the thalamocortical regions.47 The entire system is extremely important in the control of
concentration, alertness, arousal, mood, sleep/wake cycle, emotions, blood pressure
and pain regulation.47,48,49 Depression is thought, in part to be caused by dysfunction of
any of these pathways. It is thought that post-synaptic α1, α2 receptors in the frontal
cortex play a significant role in mood, attention and comprehension.47

The Norepinephrine Transporter
The norepinephrine transporter was isolated in 1991 by expression cloning; the gene
is located on human chromosome 16q 12.2.49 The amino acid sequence of the
transporter predicted a protein of 617 amino acid which contain 12 transmembrane
domains. The structure of the transporter is homologous to other transporters of
monoamine neurotransmitters (e.g. dopamine, serotonin, etc). This group of
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transporters are members of a larger group of sodium and chloride dependent transport
proteins located in neuronal and glial plasma membranes.42,49 The reuptake of
norepinephrine by the norepinephrine transporter is primarily how the synapse is
cleared and how the biological effects of the neurotransmitter are ceased. Of the
synaptic norepinephrine, 70-90% of it is cleared by the transporter while the remaining
10-30% goes into circulation or spills into extraneuronal tissue.49 In particular, cardiac
noradrenergic synapses tend to be three times narrower than distances of synapses in
the vasculature and the extraneuronal uptake (uptake-2) plays only a small role in
cardiac norepinephrine clearance.49 These observations suggest that the heart is more
dependent on the norepinephrine transporter for norepinephrine clearance of synapses
in the vascular beds. It follows that any impairment of the norepinephrine transporter
should lead to an increase in norepinephrine levels in the synaptic clefts of the heart.49

Serotonin, Receptors and Transporter
The behavioral effects of serotonin are complex and its roles range from mood
regulation, appetite, sleep, arousal, sex, regurgitation, perception, motor function,
gastrointestinal function, neurotrophism, vascular function, dreaming and regulation of
pain.45,50 Serotonergic neurons are found in nine clusters in the brain, many of which
are located within the raphe nuclei of the midbrain, pons and medulla. Two principal
clusters are the dorsal (D-system) and medial raphe nucleus (M-system). The axons of
both these clusters project into the cerebral cortex. The dorsal raphe nuclei innervates a
part of the hippocampal formation called the dentate gyrus. The two systems have other
distinguishing features as well.
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The D-system axonal fibers are thin with spindle-shaped varicosities that appear not
to form synapses with other neurons. Instead, the varicosities release serotonin that
then diffuses throughout the system. The M-system axonal fibers are thick and its
varicosities are rounded - appearing much like beads along a string. Unlike the Dsystem varicosities, these appear to be adjacent to post-synaptic membranes forming
conventional synapses.45

Serotonin Receptors
Seven families of serotonin receptors have been described, and along with them
many subtypes have also been reported. The families are referred to as 5-HT1-7, with
subtypes being referenced as a letter after the number (e.g. 5-HT1a). All of these
receptors are metabotropic except for 5-HT3 which is ionotropic.45 It has also been
observed that these subtypes have further variants due to alternative splicing, leading to
isoforms. Alternative splicing appears to be fairly common with several of the subtypes
(5-HT2C, 5-HT4 and 5-HT7).50 These variants may range from being severely truncated
and having no obvious function (5-HT2C), to differences in length and composition in the
carboxyl terminus (5-HT4(a) - 5-HT4(f), 5-HT7(a) - 5-HT7(d)).50 Further variations of the 5HT2C receptor involve RNA editing which was the first G-coupled protein found to be
edited. These variations of subtypes could present more of a challenge to the
development drugs targeting these receptors (which isoform to test), but also present
the possibility of further specification of the drug target for optimum binding.
The 5-HT1 has high concentrations of 5-HT1a binding sites and mRNA expression in
many areas throughout the brain (dorsal raphe nucleus, hippocampal pyramidal cell
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layer, cerebral cortex).50 All members of the 5-HT1 family tend to have inhibitory effects,
whether they are pre- or post-synaptic.45 This appears to be accomplished by the
opening of inwardly rectifying K+ channels or a closing of voltage-gated Ca2+ channels,
which induces hyperpolarization.50 The 5-HT1b and 5-HT1d serve as presynaptic
autoreceptors. In both the D- and M-systems, the 5-HT1a receptors serve as
autoreceptors in the membranes of both the dendrites and somas.
All 5-HT2 receptors tend to have slow excitatory effects through a decrease in K+ or
an increase in non-selective cation conductance.45,50 These effects have been observed
in various regions throughout the brain from motor neurons to the nucleus accumbens,
cerebral cortex and the substantia nigra pars reticulata. Studies have shown that these
receptors have high concentrations of binding sites and mRNA in some regions of the
forebrain (neocortex, piriform cortex, claustrum and olfactory tubercle).50 Outside of the
motor nuclei and the nucleus tractus solitarius, these receptors and their mRNA are
found at low concentration within the spinal cord and brain stem.50 These receptors are
also highly expressed in the motorneurons of the face. These receptors are also known
to play an important role in cortical information processing.
The 5-HT3 subtype can produce either excitatory or inhibitory effects. 5-HT3 can
produce an inhibitory effect on postsynaptic potentials through a chloride ion channel.
The excitatory responses attributed to this receptor are typically rapid onset and rapid
sensitization (typical of ligand-gated ion channels).50 This subtype can cause inhibition
in a round-about way by exciting inhibitory interneurons (GABAergic).50
The 5-HT4 receptors are found in several regions of the mammalian brain (striatum,
substantia nigra, olfactory tubercle and hippocampus). Since these regions also show
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significant levels of 5-HT4 mRNA suggesting that these receptors probably function
post-synaptically, in order to mediate some actions of serotonin. In the hippocampal
pyramidal cells of the CA1 region, these receptors have been shown to mediate an
inhibition of calcium activated potassium current which is ultimately responsible for the
cells ability to respond to excitatory inputs with "a robust spike activity."50
The 5-HT5 receptor appear to be relegated to the central nervous system, though its
role therein is not well characterized, although some studies suggest that it may play a
role in neuroendocrine secretion.51 While two subtypes (5-HT5a, 5-HT5b) have been
found in humans, only one (5-HT5a) appears functional.52 5-HT6 receptors are almost
exclusively located in the limbic and cortical regions.53 These receptors regulate
cholinergic and glutamatergic activity and may play some role in cognition, mood,
seizures and feeding.53 5-HT7 receptors are found in both the central nervous system
and the peripheral tissues and mediate the relaxation of smooth muscle (cardiovascular
system and gastrointestinal tract).54 In the central nervous system, these receptors
appear to play a role in the pacemaker of the circadian rhythm which is located in the
suprachiasmatic nucleus of the hypothalamus.50

Serotonin Transporter
The serotonin transporter is homologous to the norepinephrine and dopamine
transporters. The description in 1994 by Lesch et al noted that serotonin transporter
from the human midbrain raphe complex and that of platelets could be attributed to a
single copy of a gene located on chromosome 17 (17q11.1-q12).55 The human
serotonin transporter is comprised of ~630 amino acid residues and contains 12
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putative transmembrane domains. The human serotonin transporter is 92% homologous
to that of the rat. Like the other monoamine transporters, its activity is regulated by
extracellular concentrations of sodium and chloride, and is an anti-porter of potassium
ions.42,55 Unlike the norepinephrine or dopamine transporters, the activity of the
serotonin transporter is sensitive to extracellular concentrations of potassium ion. If
extracellular concentrations of potassium ion increases, or if extracellular concentrations
of sodium or chloride ions should plummet, the transporter has been noted to reverse
direction, effluxing substrates and ions.42
Genetic polymorphism of the serotonin transporter typically is seen in the promoter
region of the gene where a person has two copies of the so-called short (s) allele. This
polymorphism has been associated with decreased serotonin transporter activity in the
brain as well as decreased serotonin transporter mRNA expression and serotonin
uptake in lymphoblasts compared to a serotonin transporter with two copies of the long
(l) allele.55 The debate of whether or not this polymorphism is significant in neuroticism,
anxiety and other mood disorders is on-going. Early when this polymorphism was
reported, Lesch et al. had suggested that individuals with this polymorphism displayed
increased bias towards higher rates of neuroticism and harm avoidance than those with
two copies of the l-type allele.55 However, further studies and meta-analyses have found
conflicting results, making it seems likely that these conditions are polygenetic.

Dopamine, Receptors and Transporter
The neurotransmitter dopamine serves multiple roles dependent on its location in the
brain although it appears to always cause a slow postsynaptic effect.56 While there are
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several systems of dopaminergic neurons throughout the brain, there are three systems
of major importance that both originate in the midbrain.45 The nigrostriatal system
originates in the substantia nigra of the midbrain. The nigrostriatal system's axons
project into the neostriatum (the caudate nucleus and the putamen) which is an
important part of the basal ganglia. These neurons play an important role in movement
and Parkinson's disease. The second major dopaminergic system is that of the
mesolimbic system which originates from the ventral tegmental area (VTA) of the
midbrain. These neurons project their axons into several parts of the limbic system
(nucleus accumbens and its shell region, amygdala and hippocampus) which is known
to play a role in learning, motivation and reward. The third major system is the
mesocortical system which also originates from the ventral tegmental area. These
axons are projected to and have an excitatory effect on the prefrontal cortex. They play
a role in the function of short-term memory, strategizing and problem solving.

Dopamine Receptors
There are 5 identified subtypes of the dopamine receptor protein. These can be
broken into two homologous groups: D1-type, comprised of subtypes D1 and D5; and D2type, comprised of subtypes D2, D3, and D4.57 These two groups are similar in their
homology as well as the brain regions in which they are found, but have several key
differences. D1-like receptors are G-protein coupled receptors which are coupled to Gs
and mediate excitatory neurotransmission. Activation of these receptors activates
adenylyl cyclase which increases the intracellular concentration of cyclic adenosine
monophosphate (cAMP). These receptors mostly regulate neuronal growth and
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development, modulate D2-mediated events and mediate some behavioral responses.
Of the two D1-like receptors, D1 is the most commonly expressed throughout the brain
whereas D5 is primarily found in the limbic system.
The D2-like receptors are coupled to a different G-protein (Gαi) which directly inhibits
adenylate cyclase (thereby inhibiting cAMP production). The D2-type transporters are
found primarily in the nucleus accumbens, the ventral tegmental area and the basal
ganglia. D2-like receptors mediate inhibitory neurotransmission. Both types of receptors
are found throughout the body; notably in the cardio-pulmonary system as well as the
renal system.

The Dopamine Transporter
The role of the dopamine transporter is to transport synaptic dopamine into the cell
body. It is the primary mechanism by which synaptic dopamine is cleared. The
transporter is a plasma-membrane bound transporter protein with 12 transmembrane
domains with both the amino- and carboxyl termini within the cytoplasm.5,58 The
transporter is a symporter, which transports two Na+ ions and one Cl2- are cotransported with each molecule of dopamine.59 For each molecule of dopamine
transported into the cell, two net positive charges will also accompany it (because
dopamine is positively charged at physiological pH) and it is this movement which
generates an inward current.59 Once inside of the cell dopamine is then sequestered
into vesicles by vesicular monoamine transport protein (VMAT-2). Any dopamine that is
not sequestered by VMAT-2 is metabolized by monoamine oxidase (MAO), an outermembrane bound mitochondrial enzyme. The genetic sequence encoding the dopamine
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transporter appears to be highly conserved across species (human : monkey, 98%;
human : rat, 92%, human : bovine, 88%).60 Additionally, the DNA encoding the
dopamine transporter is very similar to the sequences of other cloned monoamine
receptors in the rat (norepinephrine transporter similarity 67%; serotonin transporter
similarity 49%, etc).60

Amphetamines Versus Cocaine
Since cocaine and amphetamines are the most popular stimulants globally, it is
important to compare and contrast their effects on their users. Cocaine shares a past
similar to amphetamines' parent compound (ephedra), as it was used medicinally for
thousands of years in the New World. Cocaine is utilized in both the free base ("crack"
cocaine) and salt forms (cocaine hydrochloride). According to the 2010 UN drug report,
there are approximately 15.9 million users of cocaine worldwide compared to 13.7 52.9 million users of amphetamine type stimulants.62 Both cocaine and amphetamines
share similar intoxicating effects on the user due to both acting as dopamine
agonists.45,63 However, there are some notable differences between the two.

Differences Between Cocaine and Amphetamine Binding and Neuronal Effects
Although both drugs act as dopamine agonists, they share several important
differences in their binding and neuronal effects. Cocaine and amphetamines directly
interact with monoaminergic neurons.31,63,64 Cocaine tends to bind at the cell surface by
inhibiting the dopamine transporter (DAT). This inhibition leads to an increased
concentration of dopamine in the synaptic cleft by preventing the re-uptake of
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neurotransmitter.31,63,64 Cocaine is not limited to interacting with the DAT, it also binds to
and inhibits other monoaminergic transporters (norepinephrine and serotonin).
Like meth- amphetamines, cocaine also acts on the vesicular monoamine
transporters (VMAT-2) by enhancing the storage of monoamines inside the synaptic
vesicles.27 Given more neurotransmitter in each vesicle, this leads to significantly
greater synaptic dopamine (or other monoamine) upon depolarization of the neuron.31
The binding and activity of amphetamines is somewhat dependent on concentration.
At low concentration, amphetamine is transported by the dopamine transporter into the
cytosol; whereas at higher concentrations, amphetamines may diffuse into the cell due
to their lipophilicity.31 Once in the cytosol, amphetamines also bind to VMAT-2;
however, unlike cocaine, amphetamines alter its function by trafficking the
neurotransmitters out of the vesicle and into the cytosol.27 At higher concentrations,
amphetamines may also diffuse into the vesicles. The ability of amphetamines to
interfere with the synthesis of dopamine is also dependent on concentration. At lower
concentrations, the drugs boost dopamine synthesis.31 At higher concentrations or
prolonged exposure, the drugs inhibit tyrosine hydroxylase or decrease the protein's
levels.31
As a weak base, amphetamines are able to accept protons from the acidic
environment of the vesicles (pH ~5.5) which leads to the alkalinization/collapse of the
proton gradient of the vesicles. This in turn nixes the active transport of amphetamines
into the vesicles.31 The weak base effect also explains mitochondrial dysfunction
induced by amphetamines in the absence of dopamine (collapse of proton gradient
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which disrupts the mitochondrial potential which may cause a decrease in intracellular
ATP).31
A study by Jones et al in 1999 showed that as the concentration of amphetamine
inside of the cell increases, this also leads to an increase in the number of inward-facing
dopamine transporters.65 These transporters then reverse their normal behavior by
transporting dopamine from the cytosol into the synaptic cleft.31,65 This leads to higher
concentrations of extracellular dopamine which can lead to neurotoxic consequences.31
The reversal of transporter direction and subsequent efflux of neurotransmitter is also
evident in the norepinephrine and serotonin transporters. Interestingly, while studies
have found methamphetamine-related neurotoxicity in regards to the dopamine and
serotonin transporters; it appears that the norepinephrine transporter is merely downregulated.66,67
Whereas amphetamines show a distinct preference for both the norepinephrine and
dopamine transporters, cocaine binds roughly equally to all three (SERT, DAT and
NET).68 Cocaine is also readily metabolized by the body and has a much shorter half-life
than amphetamines; about 0.8 ± 0.2 hours for cocaine compared to around 10.1 hours
for amphetamines.25 Peak plasma concentrations vary by method of administration and
range from 0.22 mg/L at 30 minutes for nasal administration; 0.21 mg/L at 1 h for oral
administration; 0.23 mg/L at 45 minutes for smoking (50 mg dose used).25 This is
significantly faster than the 2.6-3.6 hours it takes for peak plasma concentrations of
amphetamines.
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Long Term Effects of Cocaine versus Amphetamine Use
The long-term effects of both drugs are similar with users sharing symptoms such as
irritability, aggressiveness, stereotyped behavior and a paranoid-like psychosis.63 Like
meth- amphetamine users, chronic cocaine has been linked to neurological deficits.
These deficits include: seizures, optic neuropathy, cerebral infarction, subarachnoid
hemorrhage, intracerebral hemorrhage, multifocal cerebral ischemia, cerebral atrophy
of the frontal cortex and basal ganglia, myocardial infarction leading to global brain
ischemia, movement disorders and edema.31,69, Many of cocaine's side effects have
been reported to be caused by vasoconstriction and subsequent hypoxia, instead of the
neurotoxic mechanisms seen in amphetamines.31
Brain glucose metabolism is positively correlated to neuronal activity and cognitive
function.69 The dopamine transporter is known to play a role in glucose metabolism of
the brain, although the precise mechanism has not been discovered.69,70 Cocaine is
also known to alter brain glucose metabolism, possibly through its interactions with the
dopamine transporter. Cocaine depresses the level of glucose metabolism in the brain
both during use and during 'late-phase' abstinence.69 During the first week or so after
the start of abstinence, the user's brain has a higher than normal (read: non-user)
glucose metabolism in the medial orbitofrontal cortex and basal ganglia.71 Following this
period, glucose metabolism will fall below that of normal and persist at this level for
about three months.71 Levels of glucose metabolism in the dorsolateral prefrontal cortex
can serve as a predictor for visual and verbal memory scores.72 Glucose metabolism
levels in the anterior cingulate gyrus were also found to be predictive for
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attention/executive function (note that these detriments are still considered mild
compared to other neuropsychiatric conditions, e.g. schizophrenia).72
Similarly to meth- amphetamine use, chronic cocaine users also see a marked
decrease in dopamine receptors. These receptors (D2) are often most severely effected
in the orbitofrontal cortex and the cingulate gyrus - areas which receive the dopamine
afferent neurons. This decrease has been noted to persist despite years of abstinence.
The depletion of these receptors in combination with the decrease in brain glucose
metabolism is also seen in Parkinson's disease, a condition which has also been
associated with chronic cocaine use.
Methamphetamine use has been shown to decrease striatal glucose metabolism that
may be reflective of its selective toxicity to dopaminergic neurons.73 Users who
underwent extended abstinence showed metabolic recovery in the thalamus which may
indicate neuro-adaptations for the loss of dopamine.73

Mechanism of Amphetamine-Induced Neurotoxicity
The chronic use of amphetamines shows profound damage and cell death in areas of
the brain containing high concentrations of dopaminergic neurons. Dopamine is known
to be neurotoxic at high concentrations both in vivo and in vitro.31 The combination of
the abilities of amphetamines to efflux dopamine and inhibit its clearance from the
synaptic terminal, and the fact that these molecules have a long half-life creates an
extremely problematic scenario. Dopamine is easily oxidized by both enzymatic and
non-enzymatic mechanisms which may lead to oxidative stress in the dopaminergic
neurons as well as surrounding brain tissue (Figure 3 A).31 Auto-oxidation of dopamine
leads to the production of superoxide ion (O2·-) and hydrogen peroxide.31 Both hydrogen
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peroxide and superoxide may then interact with transition metals in a HaberWeiss/Fenton reaction to give the hydroxyl radical (·OH). Superoxide can also interact
with nitric oxide to produce peroxynitrite (ONO2-), another powerful oxidant. There are
some neuro-protective enzymes that mediate the toxic effects of these chemicals.
Hydrogen peroxide can be dulled by glutathione peroxidase which catalyzes one
molecule of hydrogen peroxide to two molecules of water (Figure 3 B). Superoxide
dismutase (SOD) catalyzes a reaction which produces diatomic oxygen and hydrogen
peroxide which may contribute to the high levels of hydrogen peroxide.
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Figure 3 - Dopamine Neurotoxicity(A) and Inactivation of Hydrogen Peroxide via
Glutathione Peroxidase (B)
A:

B:

GSH = Glutathione monome; GSSG = Glutathione disulfide.
(B) Adapted from a figure by Tandoğan and Ulusu.74

Cell death due to reactive oxidizing species is often due to the oxidation of
macromolecules (amino acids, phospholipids, nucleic acids, etc). In a normal system,
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acute exposure to hydrogen peroxide leads to apoptopic cell death. In the system of a
chronic amphetamine user, there is evidence of cell resistance to acute toxicity due to
higher levels of antioxidant enzymes in several areas of the brain.75
Developmental Approaches for Pharmacotherapies of Psychostimulant
Dependence
Two major drug classes exist for drugs targeting neuro-transporters, releasers and
re-uptake inhibitors.76 Releasers work by promoting efflux of a neurotransmitter by way
of a transporter mediated exchange (e.g. extracellular methamphetamine for
cytoplasmic dopamine), and also disrupt the storage of neurotransmitters in vesicles,
increasing their concentration in the cytoplasm.76 Re-uptake inhibitors work by binding
to the transporter and preventing the reuptake of the neurotransmitter from the synapse
in order to increase synaptic concentration.
There are several approaches in the development of pharmacotherapies for
psychostimulant addiction. Two major approaches exist; that of an agonist based
pharmacotherapy and the dual deficit approach.76 The agonist approach involves
increasing the release and/or concentration of a particular (or several)
neurotransmitters, which is thought to help with cravings and withdrawal symptoms.
Two well known antagonists are bupropion (Wellbutrin or Zycam) and modafinil
(Provigil, Alertec).77,78 Bupropion acts by inhibiting the reuptake of norepinephrine and
dopamine, of which it is twice as selective in preventing reuptake of dopamine than
norepinephrine. It has also been implicated as being a dopamine and norepinephrine
releaser.79 For these reasons, it was recently tested for its possible effectiveness as a
pharmacotherapy for methamphetamine abuse.77 While the drug was found to be
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effective in 'light' users, chronic users who would benefit the most, showed no
effectiveness. Similarly, the narcolepsy drug modafinil also works as a dopamine and
norepinephrine releaser/reuptake inhibitor. A recent study found no clear evidence of
any decrease in methamphetamine use when users were taking this drug. Other
agonists showed a similar trend of failure.76,77,78
The major issue with treating psychostimulant addiction with dopaminergic agonists
is that their mode of action creates abuse liability.76 Activation of the mesolimbic
dopaminergic while mediating some of the effects of withdrawal, can create similar
circumstances in the neurocircuitry that may prompt addiction. Research has suggested
that interplay between dopaminergic and serotonergic systems may hold the key to
reducing the liability of psychostimulant pharmacotherapies.76
The dual deficit approach is an alternative that relies on the action of two
neurotransmitter systems (serotonin and dopamine), rather than focusing on just one. It
is centered on the observation of disruption in the serotonergic and dopaminergic
systems in substance abusers.76 The withdrawal experienced by psychostimulant
abusers includes symptoms that have underlying causes that are typical of low
serotonergic and dopaminergic activity (e.g. anhedonia and craving; obsessive thoughts
and impulsivity, respectively; Figure 4). This observation has been shown to be
accurate in human brain imaging studies which have shown a marked reduction in
evoked dopamine release and D2 binding potential in the striatum, as well as
diminished response in serotonin releasers in abstinent cocaine users.76 By focusing on
both the dopamine and serotonergic pathways, the increased activation of the
serotonergic neurons should provide an inhibitory effect on mesolimbic dopamine. This
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should reduce the abuse liability for these pharmacotherapies, as well as alleviating the
symptoms of depressed serotonergic activity.76
Figure 4 - Schematic of Dual Deficit

Figure based on Rothman, Blough and Baumann.76

Compound Classification, Binding Affinities and Calculation of Inhibition
Constant
Compounds may be classified by their effects once bound to a receptor. Structures
which bind to the receptor and cause a cellular response are termed agonists. A full
agonist has maximal effect on the desired receptor. Partial agonists are structures
which can dampen the effects of the original substrate and can act as antagonists in the
case of overexposure to the substrate (these compounds have less than a full agonist
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effect on the receptor). Inverse agonists are compounds which bind to a receptor and
initiate the opposite response of the agonist. Antagonists are compounds which bind to
the receptor but cause no cellular response. These compounds have affinity for the
receptor, but lack efficacy (their only effect is to prevent another substrate from acting).
In the case of drugs of abuse, an antagonist is sought to block the receptors from
binding the ingested drug and therefore preventing the high. In order to evaluate the
effectiveness of these analogs, either a Ki or IC50 value is used. The Ki value is defined
as the dissociation constant for the enzyme-inhibitor complex (Figure 5). The smaller
the value of the Ki; the more potent the inhibitor. Since the Ki value is a rate constant,
one finds its value by determining enzyme-catalyzed reactions while varying the
concentrations of substrate and inhibitor.80 In general, the method of establishing the Ki
value is much more intensive than generating the IC50, although the IC50 may be used
to calculate a Ki.
The IC50 value is a quantitative measurement of the amount of substance needed to
inhibit a specific enzyme concentration by half. Like the Ki value, a low IC50 number
means less compound is required to inhibit 50% of the normal activity of an enzyme.
The IC50 value is determined by using one concentration of enzyme over a range of
inhibitor concentrations.80 This allows for a much quicker assessment of compounds,
especially when a series must be tested.
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Figure 5: Competitive Inhibition

Adopted from Silvermann.81

Calculating the Ki of a receptor or enzyme can be achieved by multiplying the
concentration of inhibitor and enzyme and then dividing the product by the
concentration of enzyme/inhibitor complex (Figure 6a). In order to calculate the IC50
from the Ki value, the Cheng-Prusoff equation (Figure 6b) can be used. While using this
formula (Figure 6b) provides an only approximate value of Ki, the fact that it is quick to
calculate allows for a fast screening of many compounds for evaluation.81
Figure 6: Ki Formulas
a) Ki = ([E][I])/ [EI])
b) Ki = _IC50_
( [S]/Km )
* Km is the equilibrium constant for the enzyme/substrate complex.

Synthetic Targets
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Given the structural similarity between amphetamines and other endogenous
neurotransmitters (Figure 7), we decided to examine the binding affinities for azetidinering based analogs (24 and 25). This template gives a more rigid placement of the
nitrogen as well as provides a chance to examine the effects of olefination on the
carbon chain. This also gives a slight difference in the length of the chain as well as a
slight difference in angle of the nitrogen. The goal was to examine how these changes
impact binding at the desired transporter.
Figure 7:

Previous studies have focused on the substituents on the phenyl ring and various
modifications to the two carbon linkage and the alpha methyl group (Table 3).
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Table 3: Comparison of Releasing Activity of Amphetamine Analogs
EC50 (nm)
Compound

Name

26

Structure

DAT

NET

SERT

Phenylpropylamine

1491

222

-

27

p-methylamphetamine

44.1

22.2

28

p-chloroamphetamine

68.5

23.5

-

29

p-fluoroamphetamine

51.5

28

-

30

m-chloroamphetamine

11.8

9.4

-

31

m-methylamphetamine

33.3

18.3

-

36

Phentermine

262

39.4

3511

-

Data from Blough34.
The modification of the two carbon linkage to that of a three carbon linkage greatly
increases the amount required for activity at the dopamine and norepinephrine
transporters. Similarly, an additional methyl group attached at the alpha carbon also
increases concentrations required for all three transporters' activity. Substitutions on the
aromatic ring are well tolerated and seem to follow a meta > para preference.
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The releasing activity of other, amphetamine-like compounds were also recently
examined for their releasing activity (Table 4). These compounds have more hindered
amines, either heterocyclic (33-36, 38), or additional substituents (34, 37) while
retaining the two carbon linkage of meth- amphetamine. Some of these compounds (34
and 37) show inhibition activity at the dopamine transporter. This inhibition is desirable
as the compound shows no releasing activity as well as providing a longer presence of
dopamine within the synaptic cleft (aiding in withdrawal). It is hoped that the structure of
the azetidine analogs are similar enough to share this inhibition as well as inhibition at
the serotonergic transporter. The evaluation of the azetidine system represents a novel
structure for this pursuit.
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Table 4: Comparison of releasing activity of other compounds
EC50 (nm)

Compound

Name

33

DAT

NET

SERT

Phenmetrazine

131

50.4

-

34

Phendimetrazine

Inhibitor

Inhibitor

-

35

Aminorex

49.4

26.4

-

37

Fenfluramine

Inhibitor

739

79.3

38

dl-Threo-methylphenidate

17 +/- 2.0

-

>1000

(Ritalin)

Structure

**

Data from Blough34.
**

- Data from Meltzer et al J Med Chem 2003.83

Synthetic Routes for the Azetidine Ring System
Syntheses for the azetidine ring system have been reported since the 1888.84 The
early syntheses involved extremely low yields (<1%) and were relatively infeasible for
library development. Due to the constrained nature of the ring, high yielding procedures
for azetidine synthesis are a relatively new development in chemistry. The first high
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yielding azetidine synthesis did not occur until 1967 (Scheme 1).85 Gaertner's synthesis
focused on primary hindered amines (t-butylamine, 37). While this method offered good
yields, it suffered from very slow reaction time (2.5 months), as well as being untested
for secondary amines or for less hindered N-substituted azetidines (e.g. N-benzyl).
Scheme 1

In 1968, Chatterjee and Triggle reported a modified version of this synthesis, but
failed to present any experimental data along with this publication.86 A few years later,
Anderson and Lok (Scheme 2) in 1972 published a new modification that offered much
higher yields with a bulky substituent and a significantly faster reaction time (~6 days).87
Scheme 2

This procedure is also one pot, but also has the added benefit of a removable
nitrogen protecting group. This allows not only for easier manipulation at the 3-position,
43

but prevents side product formation at the nitrogen. This also opened the door for future
modifications at the amine. The down side to this synthesis is the long reaction time as
well as the fickleness of the starting material to react. Many labs have published slight
modifications of this reaction claiming faster reaction times and superior results.88-90
The generation of the azetidine ring can be accomplished via other methods as well.
A recent paper by de Kimpe et al published a two step procedure involving the
formation of the imine and subsequent reduction into the azetidine ring (Scheme 3).91 A
modification of this procedure was also developed in our labs using benzaldehyde
starting material.92 These procedures have their strength in the ease in which one can
generate less-hindered azetidine systems. Both procedures were attempted during the
course of this work.
Scheme 3

Synthetic Strategy
Our strategy illustrated in Scheme 4, centered around the formation of a key
intermediate, the N-benzhydrylazetidin-3-one (45). From there, we could perform a
Wittig olefination to create the benzylidene 46 which would allow us to generate several
classes of compounds for evaluation and SAR development. From the benzylidene 46,
a deprotection could allow us to test the 3-benzylidene oxalate series 24 or we could
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perform a series of N-alkylations to generate N-substituted azetidines 48. The
benzylidene could also undergo hydrogenation to introduce a bit more conformational
freedom to afford 3-benzylazetidine derivatives 25.
Scheme 4

45

RESULTS AND DISCUSSION
Attempted Synthesis of Azetidine Ring
When we first approached this project, we searched for a commercially available
source for N-benzhydryl-azetidin-3-one (45). Unfortunately, the prices for what was
available at the time made this unreasonable. So we examined several routes to form
the azetidine ring. The first of which was an attempt to replicate a method which was
developed by a previous group member.92 The reaction that was developed in our lab
used benzaldehyde instead of benzophenone. It had been noted that the N-benzylazetidin-3-one was not as stable as we would have liked, and had a half-life of about
eight hours at room temperature. It had been shown that the N-benzhydrylazetidin-3one was stable for months at a time at room temperature, which made it ideal for library
development.93 The N-benzhydrylazetidin-3-ol (43) thus became our target.
Scheme 5:

As illustrated in Scheme 5, we attempted to prepare the N-benzhydryl-3,3dimethoxyazetidine 52. After numerous attempts, we were unable to achieve the
synthesis of acetal 52. It had been noted in previous studies that excess of the boron
trifluoride diethyl etherate was deleterious to the reaction yield.92 It had noted that
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anything more than a few drops negatively impacted yields. So the reaction was
repeated paying careful consideration to the amount of the catalyst, but after multiple
attempts there was no improvement in yield. Therefore we abandoned this route and
examined a similar method put forth by the de Kimpe group (Scheme 6).91
Scheme 6:

In the De Kimpe procedure (Scheme 6) magnesium sulfate was used in place of
boron triflouride diethyl etherate as a Lewis acid catalyst. However, this mild
modification did not furnish the desired acetal 52. After this reaction similarly failed, we
set about to see if perhaps there was some unidentified problem with the method. The
reaction sequence was repeated (Scheme 5) with benzaldehyde. The procedure
afforded the 3,3'-dimethoxyazetidine 44 in good yield.
Based upon these results we more closely examined why the benzophenone
reactions were failing. An NMR study of both reactions was performed. It was clear from
the NMR that after formation of the imine 51, the reductive alkylation did not take place
and only benzhydrol was observed resulting for the reduction and hydrolysis of the
imine 51. At this point, it became clear that the benzhydryl- group was much more easily
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hydrolyzed than we had originally anticipated; so we searched for new route to achieve
the desired cyclization.
A search of the literature turned up another method, specifically designed for the
synthesis of benzhydryl azetidinols. Unlike the procedures above, this reaction started
with benzhydrylamine and epichlorohydrin. The reaction involved attack of the amine at
the chloride bearing carbon which takes place over the course of the first three days,
and subsequent epoxide opening and then azetidine formation. Ultimately, the scheme
put forth by Anderson and Lok (Scheme 7) proved to be successful in synthesizing the
N-benzhydrylazetidin-3-ol (41) in good yield.87
Scheme 7:

Unfortunately, this reaction suffered from two major draw backs; variability and long
reaction times (6-7 days). At times the reaction would give good yields (72%) of a an
easily purified product. Other times, the reaction would generate only viscous yellow
residue that despite additional reaction time, yielded none of the desired product.
Attempts were made to gauge the source of the variability of the reaction; after repeated
syntheses we determined that impurities in the benzhydrylamine (40) were a key factor.
The amine that was used in this work has a 97% purity from the vendor. The best
results had been noted to occur from the use of a newly arrived and freshly opened
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bottle of the benzhydrylamine. At times, bottles from our vendor would arrive with small
precipitates formed. We reasoned that these precipitates were normal to the compound,
and perhaps were un-reacted starting material. We noted that unopened containers of
the amine in our labs would also form precipitates the longer they sat in our labs. These
precipitates would grow over time to the point where they would comprise most of the
sample. Later, we would find that exposure of benzyhdrylamine to carbon dioxide forms
impurities that are known but not fully characterized by the vendor.
These impurities in the starting material further complicated the issue of long reaction
time. Normally, the long reaction time could be overcome by scaling up the reaction so
that enough material would be generated for numerous subsequent reactions. Due to
the variability of this reaction, if a scaled up reaction were to fail, it would take another
week to run another reaction and yet another if more of the amine had to be ordered.
This could put work potentially one to two weeks behind, making scale up an
improbable and cost ineffective solution to our problem.
We looked again at the literature and found that there were some variations of our
previous method. It was thought that at least one of these methods would dampen the
interference of impurities in the reaction and perhaps cut down on the reaction time
needed. These variations altered both solvents and reaction time (Schemes 8-10), but
these were also ultimately abandoned given their much lower (if any) yields.88-90
The first of these modifications was put forth by a patent by Aventis (Scheme 8).90
The procedure in the patent promised a much shorter reaction time in a one pot
reaction. The patent starts with freebasing the amine hydrochloride before the addition

49

of epichlorohydrin and subsequent azetidine formation that takes place over the period
of several hours. The use of the more stable benzhydrylamine salt should have cut
down on the variability of this reaction. Unfortunately, the only thing we were able to
produce with this procedure was a brown sludge. The time frame suggested by the
patent seemed at odds with what we were seeing occur in our flasks (and yield wise),
so after several failed attempts we pursued other schemes.
Scheme 8:
OH
NH2

HCl

N
+
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The next method was published by Okutani et al (Scheme 9).88 This procedure
breaks the one-pot synthesis of Anderson and Lok into two separate steps with different
solvents. The first involves the formation of the epoxypropylamine 54 that takes place in
hexanes over the period of 24 h. After this step in the reaction is completed, the solution
is evaporated under reduced pressure and then dissolved in acetonitrile and refluxed.
This part of the synthesis takes 3 days, similar to the Anderson method but takes off two
days of the initial reaction. We repeated this synthesis several times with yields ranging
from around 10-59%. Unfortunately, this method also suffered from similar issues of
variability due to its use of benzhydrylamine and a lengthy reaction time.
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Scheme 9:

The last modification we tried was put forth by Oh et al, and it is very similar to the
Okutani method (Scheme 10).89 Unlike the other methods, this suggested a purification
of the 2,3-epoxypropylamine (54) before the cyclization with triethylamine. It was
thought that the inclusion of the purification step would allow for a more easily isolatable
azetidinol 41.However, we found that at least two columns were required in order to
successfully purify the 2,3-epoxypropylamine 54. The multiple purifications required to
isolate 54 resulted in an overall increase in time required for this procedure. This
resulted in nullifying our goal of a shorter (overall) reaction time. The cyclization of both
purified and crude materials were attempted and similarly failed. The combination of
failed azetidine synthesis and a similar lab time (~5 days) led to this route being
abandoned.
Scheme 10:

The reactions that performed the best for us were Anderson and Lok (Scheme 7) and
Okutani et al (Scheme 9). While the two procedures suffered notable problems, their
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ability to give good yields and ease of product isolation were desirable. At this point,
enough the benzhydrylazetidin-3-ol had been synthesized through various methods that
we could proceed with the multiple oxidations to the azetidin-3-one (45). The first
procedure we used was one by Morimoto for the oxidation of 1-diphenylmethylazetidin3-ol (Scheme 11).93 They used a variation of the Swern oxidation, the Parikh-Doering, to
generate the desired N-benzhydrylazetidin-3-one (45). Morimoto and other groups
claimed fast reaction time (30 min-1.5 h), mild conditions (room temperature), and good
yield.93,94
Unlike Swern oxidation, the Parikh-Doering uses pyridine sulphur trioxide complex
and DMSO to generate the oxidizing species (alkoxysulfonium ion). The reaction
involved first adding anhydrous DMSO to a flame dried round bottom flask which
contained the azetidinol. Triethylamine was then added and allowed to stir at room
temperature before the addition of pyridine-SO3 complex in DMSO. The appearance of
a yellow color had been noted as an indicator of the success of the oxidation. While we
did sometimes observe the appearance of a yellow when the pyridine sulfurtrioxide
complex was added, subsequent Wittig olefination of the crude generated very little
product. TLCs of the crude ketone showed multiple spots. Since the ketone 45 has
been noted to be stable at room temperature, it appeared that that the problem was not
due to the degradation of 45, but low conversion of the starting material. The scheme
was repeated with longer reaction times, but yielded similar results.
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Scheme 11:

Since the Parikh-Doering procedure failed to yield much of our desired product, we
decided to try a traditional Swern oxidation (Scheme 12).95,96 The oxidizing species can
be generated either by the use of trifluoroacetic anhydride or oxalyl chloride. Care must
be taken to keep the reaction at low temperature (at least -30°C when using TFAA and
-60°C with oxalyl chloride), as intermediates are known to be unstable. Both reagents
are extremely reactive to DMSO and without the use of solvent, can be explosive when
mixed.
Keeping this in mind, we fitted a dried reaction flask with anhydrous dichloromethane
before placing it on a dry ice/isopropanol bath at -78°C. A nitrogen atmosphere was
established in the flask before the addition of oxalyl chloride. We next added anhydrous
DMSO drop-wise into the solution. The temperature of the reaction was carefully
monitored throughout the experiment, especially during the addition of DMSO. After
allowing the mixture to stir for 20 minutes or so, the alcohol in anhydrous
dichloromethane was added. This is allowed to stir at -78°C for an hour before
triethylamine is slowly added. The reaction is then allowed to come up to room
temperature over night. Using this methodology, the azetidinone was able to be
generated but was not isolated. The crude was dried under vacuum for several hours
before being submitted to Wittig olefination. This resulted in a complex mixture of
53

product and side-products and after several columns, we decided to re-evaluate our
overall synthetic approach.
Scheme 12:

Up until this point in time, we had focused on a benzhydrylazetidin-3-one as our key
intermediate. Our initial searches for a commercial supplier yielded very few actual
vendors. Of those vendors, their prices for the intermediate were well above what we
considered reasonable for library development. Now that some time had passed, a new
search revealed that a new supplier had the N-boc-azetidin-3-one available for a good
price with high purity (5 g, $125) as opposed to previous suppliers. The decision to use
commercially available starting material saved substantial lab time and money via the
elimination of several synthetic steps.
With the N-boc-azetidin-3-one in hand, the reaction scheme was considerably
shortened. Our next target was the synthesis of phosphonium salts (Scheme 13).97 The
preparation of the Wittig reagent was easily set up and purification was very simple.
Triphenylphosphorane and the appropriate benzyl bromide were heated to reflux in
toluene. The reaction was allowed to reflux over night and in the morning, was allowed
to cool and the precipitate was filtered, washed and dried under reduced pressure. This
reaction provided excellent yields (72-98%) part of the desired phosphonium salts.
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Yields were considerably better when the benzyl bromide was used instead of the
chloride (15% for 3-fluorobenzyltriphenylphosphonium chloride versus 71% for the
corresponding bromide), although some of the benzyl halides were only available as the
chloride (4-methoxybenzyl chloride). The yields of the phosphonium salts are
summarized in Table 5.
Scheme 13:
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Table 5: Summary of triphenylphosphonium salts 57
Compound

X

Y

Yield (%)

57a

H

Br 98

57b

4-CH3

Br 86

57c

4-OCH3 Cl 72

57d

4-CF3

Br 98

57e

2-F

Br 77

57f

3-F

Br 71

57g

4-F

Br 99

57h

3,4-Cl2

Br 91

57i

3,5-F2

Br 99

57j

2-Cl

Br 94

57k

3-Cl

Br 94

57l

4-Cl

Br 95

57m

3,4-Cl2

Br 65

57n

4-Br

Br 97

57o

4-I

Br 77
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With both the phosphonium salts 57 and the azetidinone 58 in hand, the olefination
could proceed (Scheme 14).97 The procedure we used involved the production of the
dimsyl sodium by heating sodium hydride in DMSO for 1 h. The original publication
called for the solution to be chilled to 5°C, but we found that at that temperature, the
entire flask of solution would end up freezing. We found that 10°C was a good
compromise, as the reaction was cool enough to handle the excess heat produced by
deprotonation of the phosphonium salt 57, yet the flask was not so cold that the DMSO
would freeze entirely. After the addition of the phosphonium salt, the solution would
generally change color to a bright orange. The flask was allowed to stir for
approximately 15 minutes so that it was uniform in color and any "clumps" would have
time to break apart. The color would generally change again once the N-boc-azetidin-3one 58 was added, usually changing to a clear yellow. After the addition, the mixture
was allowed to warm back up to room temperature over night. After an aqueous workup, the benzylidenes 59 were obtained in good yields (Table 6). The only problems that
we experienced running this reaction generally came in the form of high humidity, which
negatively impacted yields. Fortunately, unlike some of the previous syntheses the
olefination did not experience much variability at all. So the poor yield of some of these
reactions could be ameliorated by simply increasing the scale of the reaction. While this
would not improve the yield appreciably, it would allow for the generation of the desired
amount of benzylidene for testing or hydrogenation.
Scheme 14:

57

58

Table 6: Summary of 3-arylmethylene azetidine carboxylates 59
Compound

X

Yield (%)

59a

H

13

59b

4-CH3

31

59c

4-OCH3 16

59d

4-CF3

59

59e

2-F

63

59f

3-F

60

59g

4-F

61

59h

3,4-F2

18

59i

3,5-F2

20

59j

2-Cl

50

59k

3-Cl

59

59l

4-Cl

26

59m

3,4-Cl2

53

59n

4-Br

43

59o

4-I

51

59

Deprotection of the benzylidene (Scheme 15) allowed us to probe a more rigid
conformation of the azetidine analogs and how our structure would compare with the
activity of known amphetamine analogs.

Scheme 15:

While the deprotection was fairly straightforward on paper, care had to be taken
when performing the reaction. It is important for the carboxylate to be dissolved in
dichloromethane before the addition of the trifluoroacetic acid. It also was beneficial for
an excess amount of dichloromethane compared to the acid as well. We found that for a
deprotection of solution concentration of 0.06 M of the carboxylate 59, in
dichloromethane (5 mL) to 1.5-2 mL of trifluoroacetic acid worked best. Amounts less
than 1.5 mL of acid deprotected too slowly and allowed the formation of side products.
Amounts greater than 2 mL reacted quickly, but suffered from increased side product
formation. Upon the addition of the acid, the solution changed to a brownish color and
from then on had to be carefully monitored via TLC (1:4 ethyl acetate : hexanes). Most
60

deprotections carried out in this way took about twenty to forty minutes. It is imperative
that once the deprotection is finished, that the reaction be worked up quickly before
decomposition products begin to form. After work up, the azetidine is smoothly
freebased and then the oxalate salt formed.
The hydrogenated product 25 introduced a somewhat more flexible substrate for us
to evaluate (Scheme 16). Like the benzylidene 24, the position of the nitrogen and the
alpha carbon are more rigidly fixed than that of methamphetamine, but the overall
geometry is a bit less constrained than that of the benzylidene product.
Scheme 16:

Most substituents (F, CF3, CH3) were able to undergo hydrogenation by using
palladium on charcoal (10%). The chloro- and iodo- substituents required the use of
platinum oxide to prevent dehalogenation. We had attempted several hydrogenations at
room temperature using hydrogen balloons, but all of these attempts were unsuccessful
in any appreciable addition to the double bond. Therefore, we used a Parr hydrogenator
that allowed us to perform the reaction at 45 psi. Even with the hydrogenator, all of the
substituents often required at least eight hours for completion. Many benzylidenes were
very sluggish, often running 8 hours or more.
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With a series of benzylidene derivatives 24 and 3-benzylazetidine derivatives 25 in
hand, the compounds were evaluated for binding affinity at the dopamine and serotonin
receptors (Table 7). Binding affinities for the dopamine and serotonin transporters were
determined by the ability of the drug to displace the radiolabeled ligands [3H]WIN
35,428, and [3H]citalopram, respectively, from the monoamine transporters obtained
from rat brain tissue using previously reported assays.98,99
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Table 7: Binding affinities for benzylideneazetidine analogs at serotonin (SERT)
and dopamine (DAT) transporters.

SERTc
DATc
Code
X
ClogP
Ki
DAT/SERT
Ki (nM)
(nM)
TBD
24a
AF IV 123
H
2.06
TBD
TBD
TBD
24b
AF IV 109
4-CH3
2.37
TBD
TBD
24c
TBD
AF IV 133
4-OCH3
1.95
TBD
TBD
24d
1,220 28,000 ±
23
AF IV 49
4-CF3
2.82
± 50
8,800
24e
1,070
3190 ±
3
AF IV 51
2-F
2.12
± 342
322
24f
TBD
AF IV 119
3-F
2.12
TBD
TBD
24g
1,840 3,190 ±
1.7
AF IV 169
4-F
2.12
± 335
320
24h
TBD
AF IV 55
3,4-F
2.18
TBD
TBD
TBD
24i
AF IV 77
3,5-F
2.18
TBD
TBD
TBD
24j
AF IV 93
2-Cl
2.67
TBD
TBD
24k
1,330 2,820 ±
2.1
AF IV 57
3-Cl
2.67
± 140
1,080
24l
TBD
AF IV 105
4-Cl
2.67
TBD
TBD
139 ±
531 ±
3.8
24m
AF IV 175
3,4-diCl
3.28
32
162
24n
664 ± 1,520 ±
2.3
AF IV 171
4-Br
2.76
39
260
24o
TBD
AF IV 121
4-I
2.99
TBD
TBD
a
All compounds were tested as the oxalate salts. TBD To be determined
b
ClogP: see reference.100
c
All values are the mean ± SEM of three experiments preformed in triplicate.
Compound

a

b
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Data as to how benzyl substituent position effects the binding affinities is still
forthcoming as more compounds are being tested. Comparing the binding affinities of
the two fluoro-substituted analogs; 3-(2-fluorobenzylidene)azetidine oxalate 24e to the
3-(4-fluorobenzylidene)azetidine oxalate 24g, hints that placement in the ortho position
may favor binding. Of the compounds tested, lipophilicity appears to play the larger role
as the most potent compounds tend to be more lipophilic than their cohorts. The best
compound in the series was the 3,4-dichloro analog 24m which had the best binding
affinities displayed thus far, but also showed about a 3-fold preference for the serotonin
transporter versus the dopamine transporter. A similar trend was seen with the 4-bromo
analog 24n, with an almost 50% better selectivity for the serotonin transporter over the
dopamine transporter.
The hydrogenated compounds 25 followed a similar pattern, having better affinities
for serotonin transporter versus the dopamine transporter (Table 8). These compounds
have an overall lower lipophilicity (1.93-3.09 as compared to 1.95-3.28 in the
benzylidene series) than their corresponding benzylidene counterparts which may
account for the overall lower affinities. Similar to the benzylidene series, the
hydrogenated products which have higher lipophilicity display better affinity. The best
compound in the series so far has been the 4-iodo compound 25j which displays also
shows a higher affinity for the serotonin transporter than the dopamine transporter.
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Table 8: Binding affinities of 3-benzylazetidines at DAT and SERT.

Compound

Codea

X

ClogPb

SERT Ki
(nM)c
TBD

DAT Ki
(nm)c
TBD

DAT/SERT

AF IV
4-CH3
2.18
TBD
257
25b
AF IV
4-CF3
2.63
TBD
TBD
TBD
125
25c
AF IV
2-F
1.93
TBD
TBD
TBD
251
25d
AF IV
3-F
1.93
3,200 ±
5,200 ±
1.6
207
300
1400
25e
AF IV
4-F
1.93
2,730 ±
7,670 ±
2.8
187
460
338
25f
AF IV
3,4-diF
1.98
TBD
TBD
TBD
81
25g
AF IV
3,5-diF
1.98
2,800 ± 50 12,600 ±
4.5
179
1,400
25h
AF IV
4-Cl
2.48
2,250 ±
2,240 ±
0.99
231
460
310
25i
AF IV 3,4-diCl
3.09
TBD
TBD
TBD
259
25j
AF IV
4-I
2.8
455 ± 55
1,290 ±
2.8
227
400
a
All compounds were tested as the oxalate salts.
b
ClogP see reference.100
c
All values are the mean ± SEM of three experiments preformed in triplicate.
25a

It is interesting to note that the 3,5-difluoro analog 25g, displays such poor binding
affinities for both transporters. Comparing the series of products; the benzylidenes
provide better selectivity and higher affinities for the dopamine and the serotonin
transporters. Of the currently tested compounds, the data suggests that lipophilicity
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plays a significant role in the binding affinities of these analogs as the more lipophilic
they are the better their Ki value.

CONCLUSION
A series of 3-benzylideneazetidines (24) and 3-benzylazetidines (25) were synthesized
from N-Boc-3-azetidinone. N-Boc-azetidin-3-one was converted into the 3benzylideneazetidine carboxylates 59 via Wittig olefination in good yields (13-63%).
Subsequent deprotection and conversion to the oxalate salt gave the 3benzylideneazetidines (24). The 3-benzylazetidines (25) were also prepared from 59 via
hydrogenation followed by deprotection and conversion into the oxalate salt.
Based upon preliminary binding studies at the dopamine and serotonin transporters,
the 3-benzylideneazetidines (24) and 3-benzylazetidines (25) meet the pharmacophore
requirements for binding. Although the affinity of some analogues was low, the lipophilic
analogues (24m, 24n and 25j) indicate that with the proper substituent it may be
possible to develop more potent ligand. Clearly the results of these studies indicate that
the azetidine ring system could be a useful scaffold for development of novel
compounds to explore the binding motifs at monoamine transporters.
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EXPERIMENTAL SECTION
All chemicals were purchased from Sigma Aldrich Chemical Company and used as
received unless otherwise noted. Proton and carbon NMR were recorded on a Varian
400 MHz nuclear magnetic resonance spectrometer at ambient temperature in
deuterated chloroform (CDCl3) from Cambridge Isotope Laboratories Inc, unless
otherwise noted. 1H NMR chemical shifts are reported as delta values (ppm) relative to
chloroform-d (7.26 ppm). Melting points (mp) were measured with an Electrothermal R
Mel-Temp apparatus and are uncorrected.

2,2,3-tribromopropylamine hydrobromide (43)92
Hexamethylenetetramine (100 grams, 0.71 mol ) was added to a 1 L three-neck round
bottom flask where it was dissolved in chloroform (800mL). The flask was fitted with a
condenser and an addition funnel. The dibromopropene (126 g, 0.898 mol) was added
drop-wise over a period of 40 min while the mixture was heated to reflux. The solution
went from clear to a milky yellow color and refluxed for an additional 3 h. The mixture
was then allowed to cool and stand overnight. The flask was then placed on an ice bath
to precipitate the salt. The precipitate was then vacuum filtered and the salt was allowed
to air dry overnight to yield an off-white solid.
In a 3 L round bottom flask, 2 liters of ethanol were added along with 480 mL of 12N
HCl, 400 mL of H2O and the salts stirred for 1 h at room temperature and then allowed
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to stand for 24 h. This led to a precipitate which was vacuum filtered. The filtrate was
then concentrated to near 600 mL to precipitate more of the orange salt. The filtrate was
filtered again before being concentrated to dryness. This residue was then dissolved in
300 mL of water and pH adjusted with 6N NaOH to pH 13. This mixture was then
extracted with ether (3 x 100mL) and the combined ether solutions were dried over
Na2SO4, filtered and concentrated under reduced pressure. The residue was then
distilled under reduced pressure to afford the amine as an off-white solid which was
immediately used in the next step.
The amine (41.8 g, 307 mM) was dissolved in 70 mL of water and cooled to 0 C via
an ice bath. HBr (48% solution) (40.5 mL, 0.36 mol) was added slowly with stirring,
followed by slow addition of Br2 (25 mL, 0.49 mol). The mixture was stirred at room
temperature for 24 h. The mixture was then concentrated under reduced pressure to
afford the amine salt (43) as an orange-white solid ( 74 g, 49% yield). 1H NMR (400
MHz, D2O) δ 4.35 (s, 2 H), 3.82 (s, 3 H).
Attempted Synthesis of Azetidine 5292

To a 250 mL round bottom flask, the 2,2,3-tribromopropylamine hydrobromide (4.02
g, 11 mmol) was added along with a stir bar and 100 mL benzene and 10 mL of water.
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Next, 4,4’-dichlorobenzophenone (2.78 g, 11 mmol) was added along with 2.5
equivalents of triethylamine (3 mL, 21.5 mmol). Five drops of boron trifluoride diethyl
etherate were added to promote the reaction. A Dean Stark trap was fitted to the
reaction apparatus to siphon off any of the water produced by the reaction, to help drive
the equilibrium. This reaction was heated to reflux and run overnight and monitored by
TLC. The reaction was then cooled to room temperature and diethyl ether was added to
precipitate the ammonium chloride salt which was then filtered. The filtrate was
concentrated under reduced pressure to afford the crude imine which was then
immediately utilized in the next step.
The crude imine was dissolved in dry methanol and placed in an ice bath under
Nitrogen. Three equivalents of sodium borohydride(1.13 g, 29.8 mmol) were added,
portion-wise over a period of forty-five minutes. The mixture was allowed to stir and
come back up to room temperature before being refluxed over night. Despite numerous
procedures and manipulations, the reduction failed to yield the acetal and instead
generated the corresponding benzhydrol.
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Anderson and Lok Procedure for the preparation of N-benzhydryl azetidin-3-ol
(41)87

A stir bar was added to a 250 mL round bottom flask that was then hooked up to a
condenser and placed on a heating mantle over a stir plate. This was then flushed with
dry Nitrogen gas for 5 min and wrapped in foil to prevent light from entering the sides of
the vessel. Benzhydrylamine (3.1 mL, 17 mmol) was added first and then 25-30 mL of
methanol. Epichlorohydrin (1.4 mL, 17 mmol) was then added to the stirring mixture
along with an additional 20-25 mL of methanol. Once the epichlorohydrin and methanol
were added, the solution was allowed to stir at room temperature for 3 d, protected from
light. After three days, the reaction was heated to reflux for 3 d. After the three days, the
mixture was evaporated under reduced pressure, revealing a thick, amber residue. The
residue was washed with acetone (3 x 30 mL) and the solid reserved. The wash can be
evaporated under reduced pressure and then refluxed in methanol for an increased
yield, but this was found to give only a fractional percentage increase. The solid was
then partitioned between ether and a 6 N NaOH solution. The ether was evaporated to
give N-benzhydryl azetidin-3-ol (41) in 48-60% yield. m.p 85-90°C (sublimation). (lit.
m.p. 113°C).87 1H NMR (400 MHz, CDCl3) δ 2.86-2.89 (m, 2 H), 3.51-3.55 (m, 2 H), 4.33
(s, 1 H), 4.46 (s, 1 H), 7.16-7.28 (m, 8 H), 7.37-7.51 (m, 3 H). 13C (400 MHz, CDCl3)
62.4, 63.6, 78.6, 127.3, 128.6, 142.2.
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Alternative Method for N-Benzhydryl Azetidin-3-ol (41)88

To a 250 mL round bottom flask, epichlorohydrin (2 ml, 2.5 mmol) was added slowly
to benzhydrylamine (3 mL, 17 mmol) in hexanes (10 mL). This was allowed to stand at
room temperature for 1 day. After the time was completed, the solvent was removed
under reduced pressure and the residue is dissolved in acetonitrile (30mL) and refluxed
for 3 days. The solution was then evaporated under reduced pressure and partitioned
between ether and 12 N NaOH. The ether layer was reserved, dried and condensed
under reduced pressure to reveal the N-benzhydrylazetidin-3-ol (2.4 g, 59%).
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Alternative Method for the synthesis of N-Benzhydryl Azetidin-3-ol (41)89

A 250 mL round bottom flask containing benzhydrylamine (1 g, 5.5 mmol) in
isopropanol (10 mL) under a Nitrogen atmosphere was placed on an ice bath (0°
C). Epichlorohydrin (0.5 mL, 5.5 mmol) was added drop-wise with stirring. The mixture
was allowed to warm up to room temperature over night with stirring. After 24 h, the
solution was concentrated under reduced pressure and the residue purified by flash
chromatography (SiO2, 10:1 hexanes:ethyl acetate). The epoxyamine 106 is dissolved
in acetonitrile (36 mL) and then added to a 250 mL round bottom flask. Three
equivalents of triethyl amine (8 mL, 57 mmol) is added and the solution allowed to reflux
for 24 h. The reaction was then cooled to room temperature and concentrated under
reduced pressure. The residue was then purified by column chromatography (2:1
hexanes: ethyl acetate), but yielded none of the desired product.
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Alternative Method for N-Benzhydryl Azetidin-3-ol (41)90
OH
NH2

HCl

N
+

53

O

NaHCO3, EtOH
Cl
38

41

The benzhydrylamine hydrochloride (0.2 g, 0.9 mmol) was added to a 50 mL round
bottom flask with stir bar. Ethanol (13 mL) was also added, along with sodium
bicarbonate (0.14 g, 1.7 mmol) was added and the flask was fitted to a condenser and
heated to 80°C. After 1 h, the reaction was allowed to cool to 55°C and epichlorohydrin
(0.2 mL, 2.47 mmol) was added drop-wise. The reaction was allowed to continue stirring
at 55°C for the next 4 hours. Next, the reaction was allowed to cool to 30°C and toluene
(15 mL) and water (15 mL) were added. The reaction was allowed to spin for 30 min.
The water layer was discarded and the organics were washed with unionized water (25
mL). Hydrobromic acid (48% solution; 4 mL) was added and the flask placed on an icebath to try to aid crystallization, but only a brown sludge was observed.
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Oxidation of N-Benzhydrylazetidin-3-ol (41) to N-Benzhydrylazetidin-3-one (45)
Parikh-Doering Oxidation94

To a 100 mL, dry round bottom flask, a solution of dry DMSO (10 mL) and azetidinol
(0.4 g, 1.7 mmol) was added. Triethylamine (0.6 mL, 4.3 mmol) and the pyridine sulfur
trioxide complex (0.602 g, 3.8 mmol) in DMSO (10 mL) were added at room
temperature and the mixture was allowed to stir for 30 min. This was then poured into
50 mL of ice water and then extracted with ethyl acetate (3 x 30 mL). The organics were
combined and then washed with water (50 mL) and dried over MgSO4 and concentrated
under reduced pressure. This reaction failed to yield an appreciable amount of the
desired azetidinone.
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Swern Oxidation95,96

To a flame dried, 250 mL round bottom flask, a stir bar and 10 mL of dry
dichloromethane were added. This was placed on a dry ice/isopropanol bath (-78°C)
and allowed to stir while being flushed with dry nitrogen. Oxalyl chloride (0.6 mL, 7
mmol) was added and allowed to stir before the slow addition of DMSO (0.6 mL, 8.44
mmol). The mixture was allowed to stir 20 min. Benzhydryl azetidinol (0.66 g, 2.75
mmol) was weighed out and dissolved in dry dichloromethane before being added dropwise to the mixture. After one hour of stirring at -78°C, triethylamine (2 mL, 14 mmol)
was added slowly. The mixture was allowed to stir and warm up over night. The reaction
was worked up by diluting it with 25 mL of ethyl acetate and concentrated under
reduced pressure on low heat. The residue was dried under high vacuum and used as
the crude in subsequent Wittig olefination.
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General Procedure A. Synthesis of Benzyl Phosphonium Salts (57)97

The benzyl halide (3 mL, 21.3 mmol) was added to a dry, 250 mL round-bottom flask
containing 1.1 equivalents of triphenylphosphine (5.5 g, 23.4 mmol). The mixture was
then dissolved in toluene (70 mL) and refluxed over night. The reaction was cooled to
room temperature and filtered. The precipitate (usually a white solid) was washed with
diethyl ether (3x50 mL) and dried thoroughly under vacuum before use.
(benzyl)triphenylphosphine bromide (57a)

General Procedure A; white solid (5.5 g, 98%). 1H NMR (400 MHz, CDCl3) δ 5.42 (d, 2
H, J = 12), 7.08-7.14 (m, 4 H), 7.60-7.66 (m, 6 H), 7.71-7.78 (m, 9 H). m.p. 280-292°C.
(lit. m.p.296-297°C).101
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(4-methylbenzyl)triphenylphosphonium bromide (57b)

General Procedure A; white solid (2.0 g, 86%). 1H NMR (400 MHz, CDCl3) δ 2.25 (d, 3
H, J = 4), 5.34 (d, 2 H, J = 14), 6.92-6.97 (m, 4 H), 7.61-7.64 (m, 5 H), 7.71-7.79 (m,
9H). m.p. 254-260°C. (lit. m.p.256-258°C).102

(4-methoxybenzyl)triphenylphosphonium chloride (57c)

General Procedure A; white solid (5.3 g, 72%). 1H NMR (400 MHz, CDCl3) δ 7.78-7.73
(m, 9 H), 7.63-7.60 (m, 6 H), 7.03-7.00 (m, 2 H), 6.66-6.64 (d, 2 H), 5.43 (d, 2 H), 3.72
(s, 3 H). m.p. 222-226°C. (lit. m.p. 228-230°C).103
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(4-trifluoromethylbenzyl)triphenylphosphine bromide (57d)

General Procedure A; white solid (4.1 g, 98%). 1H NMR (400 MHz, CDCl3) δ 5.64 (d, 2
H, J = 16), 7.29-7.36 (m, 2 H), 7.37 (d, 2 H, J = 8), 7.62-7.66 (m, 6 H), 7.75-7.80 (m, 9
H). m.p. 225-230°C.

(2-fluorobenzyl)triphenylphosphonium bromide (57e)

General Procedure A; white solid (5.6 g, 77%). 1H NMR (400 MHz, CDCl3) δ 5.34 (d, 2
H, J = 14.4 Hz), 6.81-6.86 (t, 1 H, J = 8.8 Hz), 6.99-7.04 (m, 1 H), 7.42-7.46 (m, 2 H),
7.64-7.81 (m, 13 H). m.p. 230-242°C.
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(3-fluorobenzyl)triphenylphosphonium bromide (57f)

General Procedure A; white solid (5.1 g, 71%). 1H NMR (400 MHz, CDCl3) δ 5.53 (d, 2
H, J = 16 Hz) 6.70 (d, 1 H J = 12), 6.91-6.95 (t, 1 H J = 8), 7.05-7.14 (m, 2 H), 7.637.68 (m, 6 H), 7.75-7.81 (m, 9 H). m.p. 298-308°C. (lit. m.p. 290-292°C).102

(4-fluorobenzyl)triphenylphosphonium bromide (57g)

General Procedure A.; white solid (8.7 g, 99% yield). 1H NMR (400 MHz, CDCl3) δ 5.51
(d, 2 H, J =14 Hz), 6.78-6.8 (m, 2 H), 7.12-7.16 (m, 2 H), 7.61-7.65 (m, 6 H), 7.79-7.74
(m, 9H). m.p. 297-303°C. (lit. m.p. 280-282°C).102
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(3,4-difluorobenzyl)triphenylphosphonium bromide (57h)

General Procedure A; off-white solid (4.9 g, 91%). 1H NMR (400 MHz, CDCl3) δ 5.46 (d,
2 H, J = 14.4 Hz), 6.86 (t, 1 H, J = 18.4 Hz), 6.91-6.99 (m, 1 H), 7.65-7.82 (m, 15 H).
m.p. 312-318°C.

(3,5-difluorobenzyl)triphenylphosphonium bromide (57i)

General Procedure A; white solid (7.0 g, 99%). 1H NMR (400 MHz, CDCl3) δ 5.71 (d, 2
H, J = 15.2 Hz), 6.58-6.68 (m, 1 H), 6.73 (d, 2 H, J = 8 Hz) 7.62-7.67 (m, 6 H), 7.76-7.85
(m, 9 H). m.p. 335-344°C. (lit. m.p.> 250°C).104
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(2-chlorobenzyl)triphenylphosphonium bromide (57j)

General Procedure A; white solid (4.6 g, 94%). 1H NMR (400 MHz, CDCl3) δ 5.69 (d, 2
H, J = 12 Hz), 7.13-7.22 (m, 3 H), 7.59-7.62 (m, 7H), 7.71-7.81 (m, 8 H). m.p. 197201°C.

(3-chlorobenzyl)triphenylphosphonium bromide (57k)

General Procedure A; white solid (5.8 g, 94%). 1H NMR (400 MHz, CDCl3) δ 5.55 (d, 2
H, J = 14.8 Hz), 6.80 (s, 1 H), 7.09 (t, 1 H, J = 8 Hz), 7.18 (s, 1 H), 7.63-7.66 (m, 6 H),
7.77-7.88 (m, 9 H). m.p. 296-300°C. (lit. m.p. 310°C).105
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(4-chlorobenzyl)triphenylphosphonium bromide (57l)

General Procedure A; white solid (4.8 g, 95%). 1H NMR (400 MHz, CDCl3) δ 5.71 (d, 2
H, J = 12 Hz),6.98 (t, 1 H, J = 8 Hz), 7.52-7.66 (m, 6 H), 7.75-7.86 (m, 10 H). m.p. 270275°C.

(3,4-dichlorobenzyl)triphenylphosphonium bromide (57m)

General Procedure A; white solid (3.6 g, 65%). 1H NMR (400 MHz, CDCl3) δ 5.57 (d, 2
H, J = 14.8 Hz), 6.93 (t, 1 H, J = 2 Hz), 7.194-7.256(m, 2 H), 7.63-7.68 (m, 6 H), 7.777.83 (m, 9 H) m.p. 296-305°C.
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(4-bromobenzyl)triphenylphosphonium bromide (57n)

General Procedure A; white solid (5.5749 g, 97%). 1H NMR (400 MHz, CDCl3) δ 5.55 (d,
2 H, J = 16), 7.00-7.06 (m, 2 H), 7.22 (d, 2 H, J = Hz), 7.60-7.65 (m, 5 H), 7.75-7.90 (m,
10 H). m.p. 268-272°C. (lit. m.p. 276-277°C).106

(4-iodobenzyl)triphenylphosphonium bromide (57o)

General Procedure A; brown solid (2.2 g, 77%). 1H NMR (400 MHz, CDCl3) δ 6.81-6.84
(m, 2 H), 7.5 (d, 2 H, J = 16), 7.64-7.69 (m, 12 H), 7.78-7.81 (m, 3 H). m.p. 231-240°C.
(lit. m.p. 255-256°C).107
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General Procedure B. Synthesis of 3-(arylmethylene)-azetidines (59)

To a flame dried, 3-neck 250 mL round bottom flask, 1.1 equivalents of sodium hydride
(60% dispersion in mineral oil) was added. Nitrogen was continuously blown through the
flask as 25 mL of anhydrous DMSO was added. The mixture was heated to 80°C for
about one hour. The mixture was then cooled to 5°C on an ice-bath and allowed to stir.
The atmosphere was maintained as 1.1 equivalents of the appropriate phosphonium
salt was added. The mixture was allowed to stir for ten minutes before adding 1
equivalent of N-Boc-azetidin-3-one. The mixture was allowed to warm to room
temperature and stir overnight. The reaction was worked up by being poured into an icy,
saturated sodium bisulfate solution. This was extracted with dichloromethane ( 3 x 50
mL) and dried over sodium sulfate before being concentrated. The residue was purified
via column chromatography (SiO2, 1:4 EtOAc:Hexanes).
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t-butyl 3-(4-fluorobenzylidene)azetidine-1-carboxylate (59a)

General Procedure B; white solid (0.48 g, 55%). 1H NMR (400 MHz, CDCl3) δ 1.57 (s, 9
H), 4.63 (s, 2 H), 4.80(s, 2 H), 6.22 (s, 2 H), 7.00-7.09 (m, 4 H). 13C NMR (300 MHz,
CDCl3) 28.4, 35.8, 115.6, 115.8, 128.2, 128.6, 128.7. m.p. 60-69°C. Anal. Calc. for
C15H18FNO3 : C 68.41; H 6.89; N 5.31. Found: C 77.68, H 10.67, N 2.47.

t-butyl 3-(3-fluorobenzylidene)azetidine-1-carboxylate (59b)

General Procedure B; white solid (0.46 g, 60%) 1H NMR (400 MHz, CDCl3) δ 1.63 (s, 9
H), 4.82 (s, 2 H), 4.64 (s, 2 H), 6.24 (s, 1 H), 6.77-6.79 (m, 1 H), 6.87-6.94 (m, 2 H),
7.30-7.32 (m, 1 H). 13C NMR (300 MHz, CDCl3) δ 28.9, 55.9, 114.0, 114.2, 121.6,
130.4, 135.5. m.p. 75-80°C. Anal. Calc. for C15H18FNO3 : C 68.41; H 6.89; N 5.31.
Found: C 67.79, H 6.99, N 5.14.
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t-butyl 3-(2-fluorobenzylidene)azetidine-1-carboxylate (59c)

General Procedure B; off-white solid (0.7 g, 63%) 1H NMR (400 MHz, CDCl3) δ 1.43 (s,
9 H), 4.20 (s, 2 H), 4.78 (s, 2 H), 6.5 (s, 1 H), 6.99-7.19 (m, 3 H), 7.18-7.21 (m, 1 H). 13C
NMR (300 MHz, CDCl3) 28.4, 79.9, 114.6, 115.4, 115.8, 124.2, 127.6, 128.6, 128.7. m.p
49-52°C. Anal. Calc. for C16H18FNO2 : C 68.41, H 6.89, N 5.31. Found: C 68.64, H 7.06,
N 5.14.

t-butyl 3-(3,4-difluorobenzylidene)azetidine-1-carboxylate (59d)

General Procedure B; white solid, (0.18 g, 18%). 1H NMR (400 MHz, CDCl3) δ 1.55 (s, 9
H), 4.63 (s, 2 H), 4.78 (s, 2 H), 6.18 (s, 1 H), 6.83-6.99 (m, 2 H), 7.10-7.15 (m, 1H). 13C
NMR (300 MHz, CDCl3) δ 28.6, 58.8, 115.7, 115.9, 117.7, 177.9, 120.7, 123.4. m.p.
116-120°C. Anal. Calc. for C16H17F2NO2 : C 64.04; H 6.09; N 4.98. Found: C 63.87, H
6.21, N 4.94.
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t-butyl 3-(3,5-difluorobenzylidene)azetidine-1-carboxylate (59e)

General Procedure B; white solid (0.2 g, 20%).1H NMR (400 MHz, CDCl3) δ 1.63 (s, 9
H), 4.64 (s, 2 H), 4.81 (s, 2 H), 6.2 (s, 1 H), 6.59-6.68 (m, 3 H). 13C NMR (300 MHz,
CDCl3) δ 31.2, 57.0, 101.6, 101.9, 102.3, 109.7, 109.9, 119.6, 161.6, 164.9. m.p. 118125°C. Anal. Calc. for C16H17F2NO2 : C 64.04; H 6.09; N 4.98. Found: C 63.65, H 6.32,
N 4.83.

t-butyl 3-(4-chlorobenzylidene)azetidine-1-carboxylate (59f)

General Procedure B; white solid (0.42 g, 26%). 1H NMR (400 MHz, CDCl3) δ 7.3 (d, 2
H), 7.0 (d, 2 H), 6.22 (s, 1 H), 4.8 (s, 2 H), 4.6 (s, 2 H), 1.4 (s, 9 H). 13C NMR (300 MHz,
CDCl3) 134.8, 131.7, 129.1, 128.5, 121.4, 80.1, 58.9, 28.6. m.p. 130-135°C. Anal. Calc.
for C15H18NO2Cl : C 64.4; H 6.48; N 5.00. Found: C 64.22, H 6.64, N 4.92.
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t-butyl 3-(3-chlorobenzylidene)azetidine-1-carboxylate (59g)

General Procedure B; thick, yellow oil ( 0.58 g, 59%). 1H NMR (400 MHz, CDCl3) δ 1.47
(s, 9 H), 4.64 (s, 2 H), 4.81 (s, 2 H), 6.21 (s, 1 H), 6.98 (d, 1H, J = 4), 7.18-7.28 (m, 2 H).
13

C NMR (300 MHz, CDCl3) 28.6, 58.9, 121.4, 125.4, 130.1. Anal. Calc. for

C15H18NO2Cl : C 64.4; H 6.48; N 5.00. Found: C 61.56; H 6.47; N 4.57.

t-butyl 3-(2-chlorobenzylidene)azetidine-1-carboxylate (59h)

General Procedure B; yellow oil ( 0.42 g, 50%). 1H NMR (400 MHz, CDCl3) δ 1.49 (s, 9
H), 4.67 (s, 2 H), 4.78 (s, 2 H), 6.67 (s, 1 H), 7.10-7.18 (m, 3 H), 7.38 (d, 1 H, J= 8 Hz).
13

C NMR (300 MHz, CDCl3) δ 28.6, 58.8, 80.1, 118.9, 127.1, 127.6, 128.5, 130.1, 131.8,

132.4, 132.5, 133.2, 133.4.
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t-butyl 3-(3,4-dichlorobenzylidene)azetidine-1-carboxylate (59i)

General Procedure B; white solid, (0.62 g, 53%). 1H NMR (300 MHz, CDCl3) δ 1.55 (s, 9
H), 4.64 (s, 2 H), 4.8 (s, 2 H), 6.18 (s, 1 H), 6.92 (d, 2 H, J= 7.5 Hz), 7.18 (s, 1 H). 13C
NMR (300 MHz, CDCl3) δ 28.4, 58.7, 120.5, 126.4, 129.1, 130.9. m.p. 90-105°C. Anal.
Calc. for C16H17Cl2NO2 : C 57.33; H 5.45; N 4.46. Found: C 54.65, H 5.21, N 4.17.

t-butyl 3-(4-bromobenzylidene)azetidine-1-carboxylate (59j)

General Procedure B; white solid, (0.38 g, 43%). 1H NMR (400 MHz, CDCl3) δ 1.47 (s, 9
H), 4.62 (s, 2 H), 4.78 (s, 2 H), 6.20 (s,1 H), 6.97 (t, 2 H, J = 8 Hz), 7.45 (d, 2 H, J = 8
Hz). 13C NMR (300 MHz, CDCl3) δ 28.6, 100.2, 121.5, 128.8, 132.1. m.p. 110-115°C.
Anal. Calc. for C15H18NO2Br : C 55.57; H 5.60; N 4.32. Found: C 55.28, H 5.45, N 4.35.

t-butyl 3-(4-iodobenzylidene)azetidine-1-carboxylate (59k)
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General Procedure B; yellowish solid (0.4 g, 51%). 1H NMR (400 MHz, CDCl3) δ 1.45 (s,
9 H), 4.61 (s, 2 H), 4.77 (s, 2 H), 6.18 (s, 1 H), 6.83 (d, 2 H, J = 8 Hz), 7.65 (d, 2 H, J = 8
Hz). 13C NMR (300 MHz, CDCl3) δ 28.4, 58.7, 115.6, 115.8, 128.2, 128.6, 128.7, 135.2,
162.9. m.p. 78-85°C. Anal. Calc. for C15H18NO2I : C 48.53; H 4.89; N 3.77. Found: C
50.71, H 5.11, N 3.32.

t-butyl 3-(4-methoxybenzylidene)azetidine-1-carboxylate (59l)

General Procedure B; waxy solid (0.18 g, 16%). 1H NMR (400 MHz, CDCl3) δ 1.47 (s, 9
H), 3.80 (s, 3 H), 4.61 (s, 2 H), 4.79 (s, 2 H), 6.19 (s, 1 H), 6.86 (d, 2 H, J = 4 Hz), 7.03
(d, 2 H, J = 8 Hz). 13C NMR (300 MHz, CDCl3) δ 28.6, 29.9, 55.5, 59.1, 114.4, 122.5,
127.3 (2), 127.6, 128.5, 129.9. m.p. 40-45°C. Anal. Calc. for C16H21NO3 : C 69.79; H
7.68; N 5.09. Found: C 72.46, H 8.63, N 3.92.

t-butyl 3-(4-methylbenzylidene)azetidine-1-carboxylate (59m)
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General Procedure B; white solid (0.21 g, 31%). 1H NMR (400 MHz, CDCl3) δ 1.47 (s, 9
H), 2.33 (s, 3 H), 4.62 (s, 2 H), 4.81 (s, 2 H), 6.22 (s, 1 H), 7.00 (d, 2 H,J = 8 Hz) 7.14
(d, 2 H, J = 8 Hz) 13C NMR (300 MHz, CDCl3) δ 21.4, 28.6, 29.9, 122.3, 127.3, 129.6,
133.6, 137.1, 156.5. m.p. 63-65°C. Anal. Calc. for C16H21NO2 : C 74.10; H 8.16; N 5.40.
Found: C 73.61, H 8.22, N 5.38.

t-butyl 3-(4-trifluoromethylbenzylidene)azetidine-1-carboxylate (59n)

General Procedure B; light yellow solid (0.64 g, 59%). 1H NMR (400 MHz, CDCl3) δ 1.47
(s, 9 H), 4.66 (s, 2 H), 4.84 (s, 2 H), 6.31 (s, 1 H), 7.20 (d, 2 H, J = 8 Hz), 7.58 (d, 2 H, J
= 8 Hz). 13C NMR (300 MHz, CDCl3) δ 28.6, 59.0, 121.5, 125.9 (2), 127.4, 134.2. m.p.
110-115°C. Anal. Calc. for C16H18F3NO2 : C 56.79; H 5.36; N 4.14. Found: C 61.15, H
5.81, N 4.39.

t-butyl 3-(benzylidene)azetidine-1-carboxylate (59o)
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General Procedure B; white solid (0.09g, 13%). 1H NMR (400 MHz, CDCl3) δ 1.48 (s, 9
H), 4.64 (s, 2 H), 4.83 (s, 2 H), 6.26 (s, 1 H), 7.10 (d, 2 H, J = 4 Hz), 7.20 (t, 1 H, J = 8
Hz), 7.33 (t, 2 H, J = 8 Hz). 13C NMR (300 MHz, CDCl3) δ 28.6, 58.9, 122.5, 127.3,
128.9, 136.3, 156.5. m.p. 53-58°C. Anal. Calc. for C15H19NO2 : C 73.43; H 7.80; N 5.70.
Found: C 73.61, H 8.23, N 5.17.
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General Procedure C. Syntheis of 3-Benzylideneazetidies 24

The boc-protected azetidine (0.08 g, 0.32 mmol) was added to a 50 mL round bottom
flask. It was then dissolved in 5 mL of dichloromethane and allowed to stir.
Trifluoroacetic acid (1.5 mL, 19.6 mmol) was added to the mixture and allowed to stir at
room temperature. The reaction was monitored by TLC (1:4 EtOAc:Hexanes) for the
duration of the deprotection. Once the trifluoroacetic salt had formed, the mixture was
then condensed under reduced pressure without heat.
The trifluoroacetate salt was dissolved in water (10 mL) and sodium bicarbonate was
added slowly. After reaching pH ~9, ammonium hydroxide was added in drop-wise until
pH 12. The solution was then extracted with dichloromethane (3 x 30 mL) and dried
over sodium bicarbonate. This was filtered and the organics were condensed under
reduced pressure at room temperature. The residue was then dissolved in a minimal
amount of anhydrous diethyl ether. Oxalic acid (0.032 g, 0.352 mmol) was then
dissolved in ether (5 mL) and added to the solution drop-wise. The salt was allowed to
precipitate overnight before being triturated and dried under reduced pressure.
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3-(benzylidene)azetidine oxalate (24a)

General Procedure C; white solid (0.56 g, 98%). 1H NMR (400 MHz, CDCl3) δ 2.07 (s, 1
H), 4.43 (s, 2 H), 4.61 (s, 2 H), 6.13 (s, 1 H), 7.07-7.09 (m, 2 H), 7.16-7.20 (m, 1 H),
7.29-7.22 (m, 2 H). 13C NMR (400 MHz, CDCl3) δ 57.2, 57.4, 121.1, 126.6, 128.3, 137.1,
140.3. m.p.155-165°C. Anal. Calc. for C10H10N●C2H2O4 : C 61.27; H 5.57; N 5.95.
Found: C 59.94; H 5.51; N 5.80.

3-(4-methylbenzylidene)azetidine oxalate (24b)

General Procedure C; white solid (0.19 g, 95%). 1H NMR (300 MHz, CDCl3) δ 7.16-7.11
(m, 2 H), 2.17 (s, 1 H), 2.54 (s, 3 H), 4.42 (s, 2 H), 4.60 (s, 2 H), 6.10 (s, 1 H), 6.98 (d, 2
H, J = 9 Hz), 7.12 (d, 2 H, J = 6 Hz). 13C NMR (300 MHz, CDCl3) δ 57.4, 100.2, 120.9,
127.2, 129.5. m.p. 133-140°C. Anal. Calc. for C11H13N●C2H2O4 : C 62.63; H 6.06; N
5.62. Found: 61.30, H 6.21, N 5.17.
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3-(4-methoxybenzylidene)azetidine oxalate (24c)
OCH3

O
OH

N HO
H
O

General Procedure C; white solid (0.045 g, 99%). 1H NMR (300 MHz, CDCl3) δ 2.18 (s,
1 H), 3.8 (s, 3 H) 4.42 (s, 2 H), 4.59 (s, 2 H), 6.07 (s, 1 H), 6.85 (d, 2 H, J = 9 Hz), 7.06
(d, 2 H, J = 12). 13C NMR (300 MHz, CDCl3) δ 57.2, 114.2, 120.4, 128.5. m.p.175180°C. Anal. Calc. for C11H13NO●C2H2O4 : C 58.86; H 5.7; N 5.27. Found: C 57.83; H
5.65; N 5.09.

3-(4-trifluoromethylbenzylidene)azetidine oxalate (24d)

General Procedure C; white solid (0.046 g, 98%). 1H NMR (300 MHz, CDCl3) δ 2.41 (s,
1 H), 4.46 (s, 2 H), 4.63 (s, 2H), 6.18 (s, 1 H), 7.16 (d, 2 H, J = 9 Hz), 7.54-7.63 (m, 2
H). 13C NMR (300 MHz, CDCl3) δ 57.2, 57.3, 120.2, 125.7 (3), 125.8, 127.4. m.p. 121130°C. Anal. Calc. for C11H10F3N●C2H2O4 : C 51.49; H 3.99; N 4.62. Found: C 49.65; H
4.00; N 4.59.
3-(2-fluorobenzylidene)azetidine oxalate (24e)
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General Procedure C; white solid (0.05 g, 99%). 1H NMR (400 MHz, CDCl3) δ 2.17 (bs,
1 H), 4.42 (s, 2 H), 4.60 (s, 2 H), 6.07 (s, 1 H), 6.94-6.99 (m, 1 H), 7.05 (s, 1 H), 7.457.53 (m, 1 H), 7.65-7.75 (m, 1 H). 13C NMR (400 MHz, CDCl3) δ 57.2 (2), 119.9, 125.4,
128.7, 131.8, 138.8, 142.3. m.p. 140-152°C. Anal. Calc. for C10H10FN●C2H2O4 : C
56.92; H 4.78; N 5.53. Found: C 53.56; H 4.65; N 5.04.

3-(3-fluorobenzylidene)azetidine oxalate (24f)

General Procedure C; white solid (0.0508 g, 98%). 1H NMR (400 MHz, CDCl3) δ 2.17 (s,
1 H), 4.58 (s, 2 H), 4.75 (s, 2 H), 6.14 (s, 1 H), 6.72-6.89 (m, 4 H).13C NMR (400 MHz,
CDCl3) δ 29.9, 115.6, 128.7, 128.8, 131.8 (2)m 132.4, 132.6. m.p. 62-75°C. Anal. Calc.
for C10H10FN●C2H2O4 : C 56.92; H 4.78; N 5.53. Found: C 56.15; H 4.71; N 5.28.
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3-(4-fluorobenzylidene)azetidine oxalate (24g)

General Procedure C; white solid (0.054 g, 97%) . 1H NMR (400 MHz, CDCl3) δ 2.16 (s,
1 H), 4.40 (s, 2 H), 4.58 (s, 2 H), 6.09 (s, 1 H) 6.97-7.05 (m, 4 H). 13C NMR (400 MHz,
CDCl3) δ 29.9 (3), 32.1, 57.1, 115.6, 115.8, 120.0, 128.7, 128.8, 162.8. m.p. 305-312°C.
Anal. Calc. for C10H10FN●C2H2O4 : C 56.91; H 4.77; N 5.52. Found: C 51.84; H 4.82; N
4.49.

3-(3,4-difluorobenzylidene)azetidine oxalate (24h)

General Procedure C; white solid (0.051 g, 95%). 1H NMR (400 MHz, CDCl3) δ 2.16
(bs, 1 H), 4.42 (s, 2 H), 4.57 (s, 2 H), 6.05 (s, 1 H), 6.76-6.88 (m, 2 H), 7.04-7.13 (m, 1
H). 13C NMR (300 MHz, CDCl3) δ 57.0 (2), 60.6, 115.5, 117.4, 119.3, 123.3 (2) ,123.4.
m.p. 150-158°C. Anal. Calc. for C10H9F2N●C2H2O4 : C 53.41; H 4.09; N 5.16. Found: C
52.30; H 4.00; N 5.35.
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3-(3,5-difluorobenzylidene)azetidine oxalate (24i)

General Procedure C; white solid (0.066 g, 96%). 1H NMR (400 MHz, CDCl3) δ 2.17 (s,
1 H), 4.17 (s, 2 H), 4.59 (s, 2 H), 6.07 (s, 1 H), 6.56-6.65 (m, 3 H). 13C NMR (400 MHz,
CDCl3) δ 57.1, 101.6, 101.9, 102.3, 109.7, 109.8, 109.9, 110, 119.6. 170-185°C. Anal.
Calc. for C10H9F2N●C2H2O4 : C 53.14; H 4.08; N 5.16. Found: C 43.94; H 3.91; N 6.05.

3-(2-chlorobenzylidene)azetidine oxalate (24j)

General Procedure C; pale yellow solid (0.62 g, 96%). 1H NMR (300 MHz, CDCl3) δ
1.94 (bs, 1 H), 4.47 (s, 2 H), 4.58 (s, 2 H), 6.55 (s, 1 H), 7.10-7.37. 13C NMR (300 MHz,
CDCl3) δ 29.9, 57.0, 57.3, 100.2, 117.4, 126.9, 127.7, 127.8, 130.0. m.p. 107-110°C.
Anal Calc. for C10H10ClN●C2H2O4 : C 53.44; H 4.49; N 5.19. Found: C 50.64; H 4.78; N
3.70.
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3-(3-chlorobenzylidene)azetidine oxalate (24k)

General Procedure C; white solid (0.05 g, 94%). 1H NMR (300 MHz, CDCl3) δ 2.17 (s, 1
H), 4.41 (s, 2 H), 4.58 (s, 2 H), 6.07 (s, 1 H), 6.93-7.17 (m, 4 H). 13C NMR (300 MHz,
CDCl3) δ 52.8, 55.1, 57.1, 100.2, 125.4, 126.7, 127.7, 128.6, 129.9. m.p. 155-162°C.
Anal. Calc. for C10H10ClN●C2H2O4 : C 53.44; H 4.49; N 5.19. Found: C 53.61; H 4.85; N
4.60.

3-(4-chlorobenzylidene)azetidine oxalate (24l)

General Procedure C; cream colored solid (0.06 g, 95%). 1H NMR (400 MHz, CDCl3) δ
2.17 (s, 1 H), 4.42 (s, 2 H), 4.58 (s, 2 H), 6.09 (s, 1 H), 6.99-7.01 (m, 2 H), 7.26-7.28 (m,
2 H). 13C NMR (300 MHz, CDCl3) δ 57.2, 119.9, 128.5 (2), 128.9 (2), 132.3, 135.5,
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141.2. m.p. 163-169°C. Anal. Calc. for C10H10ClN●C2H2O4 : C 53.44; H 4.49; N 5.19.
Found: C 52.2, H 4.81, N 4.67.

3-(3,4-dichlorobenzylidene)azetidine oxalate (24m)

General Procedure C; white solid (0.54 g, 98%). 1H NMR (300 MHz, CDCl3) δ 2.17 (s, 1
H), 4.41 (s, 2 H), 4.57 (s, 2 H), 6.03 (s, 1 H), 6.88 (d, 1 H, J = 9 Hz), 7.13-7.18 (m, 1 H),
7.18 (s, 1 H), 7.34-7.48 (m, 1 H). 13C NMR (300 MHz, CDCl3) δ 57.1 (2), 119.0, 126.4,
128.9, 130.6, 137.0, 142.9. m.p. 150-165°C. Anal. Calc. for C10H9Cl2N●C2H2O4 : C
47.39; H 3.64; N 4.60. Found: C 44.42; H 3.95; N 3.86.
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3-(4-bromobenzylidene)azetidine oxalate (24n)
Br

O
OH

N
H HO
O

General Procedure C; white solid (0.053 g, 99%). 1H NMR (300 MHz, CDCl3) δ 2.17 (s,
1 H), 4.40 (s, 2 H), 4.57 (s, 2 H), 6.07 (s, 1 H), 6.89-6.93 (m, 2 H), 7.37-7.56 (m, 2 H).
13

C NMR (300 MHz, CDCl3) δ 57.2, 120.1, 120.4, 128.8, 131.9, 135.9, 141.3. m.p. 178-

184°C. Anal. Calc. for C10H10BrN●C2H2O4 : C 45.88; H 3.85; N 4.45. Found: C 46.40; H
4.18; N 3.90.

3-(4-iodobenzylidene)azetidine oxalate (24o)

General Procedure C; soft yellow solid (0.52 g, 99%). 1H NMR (300 MHz, CDCl3) δ 2.78
(s, 1 H), 4.43 (s, 2 H), 4.59 (s, 2 H), 6.07 (s, 1 H), 6.82 (d, 2 H, J = 6 Hz), 7.61-7.73 (m,
2 H). 13C NMR (300 MHz, CDCl3) δ 57.1, 91.9, 120.6, 129.0, 136.3, 137.8 (2), 137.9,
138,3, 140.4. m.p. 182-188°C. Anal. Calc. for C10H10IN●C2H2O4 : C 39.91; H 3.35; N
3.88. Found: C 40.05; H 3.31; N 3.81.
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General Procedure D. Synthesis of 3-benzyl-azetidines (25)

To a hydrogenation flask, 10% wt. of palladium on carbon (0.11 g) (or other catalyst
in cases where noted) was added. The flask was then flushed with dry nitrogen for 10 to
15 minutes. A nitrogen balloon was placed on the flask and anhydrous methanol (40
mL) was added. The alkylidene 59 (0.10 g, 0.36 mmol) was then dissolved in dry
methanol (10 mL) and added to the mixture. The flask was then placed under reduced
pressure for approximately five minutes and flushed with hydrogen. The hydrogen was
then released and the flask was evacuated again before being filled with hydrogen (~45
psi) and the mixture was allowed to stir for 8 h. The catalyst was then filtered on Celite
and the filter-cake was washed with methanol (3 x 30 mL). The filtrate was then
evaporated under reduced pressure and dried under vacuum to yield the desired
compound.
In cases where hydrogenation was sluggish or there was concern for dehalogenation
of the aromatic ring, platinum oxide was used as a catalyst. To a dry, 100 mL round
bottom flask, platinum oxide (0.015g) and a stir bar were added. The flask was covered
with a septa and flushed with nitrogen for approximately five min. Dry methanol (20 mL)
was then added to the flask. The azetidine (0.08g) was dissolved in methanol and
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added to the flask. The flask was then flushed with hydrogen before being placed under
a hydrogen atmosphere and heated to 50°C and allowed to stir overnight.
In both procedures, hydrogenations were allowed to proceed until a full conversion of
starting material had occurred.

General Procedure E. Deprotection of Boc Group and formation of oxalate salt

To a dry 50 mL flask, the azetidine (0.036 g, 0.13 mmol) and stir bar were added. The
azetidine was dissolved in dichloromethane (5 mL) and then trifluoroacetic acid (2 mL)
was added with stirring. The reaction was monitored by TLC until completion. The flask
was then condensed to dryness. Water (10 mL) was added to the residue and sodium
bicarbonate was added until pH ~9. Ammonium hydroxide (~10 mL) was then added
until pH 12. This was then extracted with dichloromethane (3 x 30 mL). The organics
were dried with sodium sulfate and condensed at room temperature under reduced
pressure. The azetidine was then dissolved in a minimal amount of anhydrous diethyl
ether. Oxalic acid (0.013 g, 0.14 mmol) in diethyl ether was added drop-wise into the
solution. The salt was allowed to precipitate over night before being triturated and dried
under vacuum.
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3-(4-methylbenzyl)azetidine oxalate (25a)

General Procedures D and E; orange, oily wax-like solid (0.03 g, 97%). Boc compound:
1

H NMR (400 MHz, CDCl3) δ 7.09 (d, 2 H), 7.03 (d, 2 H), 3.97 (t, 2 H), 3.63 (t, 2 H), 2.85

(d, 2 H), 2.79-2.77 (m, 1 H), 2.31 (s, 3 H), 1.43 (s, 9 H). 1H NMR (400 MHz, CDCl3) δ
7.69-7.48 (m, 3 H) Anal. Calc. for C11H15N●C2H2O4: C 62.13; H 6.82; N 5.58. Found: C
52.85, H 8.69, N 0.89.

3-(4-trifluoromethyl)azetidine oxalate (25b)

General Procedures D and E; white solid (0.39 g, 98%). 1H NMR (400 MHz, CDCl3) δ
7.75-7.73 (m, 1 H), 7.55-7.33 (m, 3 H), 4.02-3.98 (m, 2 H), 3.65-3.48 (m, 2 H), 2.96 (s, 1
H), 2.87-2.76 (m, 2 H), 1.48 (s, 9 H). m.p. for C10H12ClN●C2H2O4: 115-130°C. Anal.
Calc. for C11H12F3N●C2H2O4: C 51.15; H 4.62; N 4.59. Found: C 48.98; H 4.80; N 4.36.
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3-(2-fluorobenzyl)azetidine oxalate (25c)

General Procedures D and E; brownish solid (0.031 g, 97%). 1H NMR (400 MHz,
CDCl3) δ 2.17 (s, 2 H), 2.91-3.00 (m, 3 H), 3.44 (s, 2 H), 3.66 (s, 2 H), 6.98-7.18(m, 4
H). 13C NMR (300 MHz, CDCl3) δ 33.6, 52.9, 115.4, 115.6, 124.3, 130.8. Anal. Calc. for
C10H12FNO●C2H2O4: C 56.46; H 5.52; N 5.48. Found: C 21.58, H 4.54, N 0.19.

3-(3-fluorobenzyl)azetidine oxalate (25d)

General Procedures D and E, white solid (0.15 g, 95%). 1H NMR (400 MHz, CDCl3) δ
2.09 (bs, 1 H), 2.81-2.96 (m, 3 H), 3.41 (s, 2 H),3.67 (s, 2 H), 6.82-6.92 (m, 3 H), 7.227.24 (m, 1 H). 13C NMR (300 MHz, CDCl3) δ 53.1, 100.2, 113.0, 113.3, 124.3, 130.1.
m.p. 50-60°C. Anal. Calc. for C10H12FNO●C2H2O4: C 56.46; H 5.52; N 5.48. Found: C
55.04, H 5.97, N 4.30.
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3-(4-fluorobenzyl)azetidine oxalate (25e)

General Procedures D and E, white solid (0.044 g, 99%). 1H NMR (400 MHz, CDCl3) δ
1.91 (s, 2 H), 2.86-2.88 (m, 2 H), 2.92-3.02 (m, 1 H), 3.40 (t, 2 H), 3.66 (t, 2 H), 6.936.98 (m, 2 H), 7.07-7.10 (m, 2 H). 13C NMR (400 MHz, CDCl3) δ 29.9, 36.5, 38.8, 53,
115.3, 115.5, 129.9 (2). m.p. 68-80°C. Anal. Calc. for C10H12FNO●C2H2O4: C 56.46; H
5.52; N 5.48. Found: C 57.96, H 6.56, N 4.36.

3-(3,4-difluorobenzyl)azetidine oxalate (25f)

Beige solid (0.54 g, 99%). Boc compound: 1H NMR (400 MHz, CDCl3) δ 1.54 (s, 9H),
2.86 (d, 2 H, J = 6 Hz), 3.98 (t, 2 H, J = 6 Hz), 6.82-6.85 (m, 1 H), 6.90-6.95 (m, 1 H),
7.02-7.09 (m, 1 H).13C NMR (300 MHz CDCl3) δ 29.9, 53.0, 117.1 (2), 117.4 (2), 124.4.
m.p. for C10H11F2N●C2H2O4 75-85 °C. Anal. Calc. for C10H11F2N●C2H2O4: C 52.74; H
4.79; N 5.12. Found: C 58.09, H 7.04, N 3.46.
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3-(3,5-difluorobenzyl)azetidine oxalate (25g)

General Procedures D and E; yellow solid (0.044 g, 99%). 1H NMR (400 MHz, CDCl3) δ
1.28 (s, 9H), 2.77-2.80 (m, 1 H), 2.89 (s, 2 H), 3.62 (s, 2 H), 4.01 (s, 2 H), 6.65-6.66 (m,
3 H). 13C NMR (300 MHz, DMSO) δ 51.0, 54.2, 112.5. m.p. for C15H19F2NO2: 50-58°C.
m.p. for C10H11F2N●C2H2O4: 100-110°C. Anal. Calc. for C10H11F2N●C2H2O4: C 52.94; H
4.44; N 5.14. Found: C 47.06; H 5.44; N 3.52.

3-(4-chlorobenzyl)azetidine oxalate (25h)

General Procedures D and E; white solid (0.1 g, 99%). 1H NMR (400 MHz, CDCl3) δ
2.05 (s, 1 H), 2.86-2.95 (m, 2 H), 3.28 (m, 1 H), 3.40 (s, 2 H), 3.65 (s, 2 H), 6.99-7.15
(m, 2 H), 7.19-7.23 (m, 2 H) 13C NMR (300 MHz, CDCl3) 14.3, 22.9, 29.9, 53.1, 128.7,
129.9. m.p. for C10H12ClN●C2H2O4: 110-120 °C. Anal. Calc. for C10H12ClN●C2H2O4: C
53.04; H 5.19; N 5.15. Found: C 54.2, H 6.00, N 4.06.
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3-(4-iodobenzyl)azetidine oxalate (25j)

General Procedures D and E; white solid (0.1 g, 93%). 1H NMR (400 MHz, CDCl3) δ
1.43 (s, 9 H), δ 1.42 (s, 9 H), 2.75-2.79 (m, 1H), 2.86 (d, 1 H, J = 16 Hz), 3.59-3.64 (m, 2
H), 3.95-4.00 (m, 2 H), 6.97 (d, 1 H, J=6 Hz), 7.05 (d, 1 H, J = 12 Hz), 7.19 (d, 1 H, J = 8
Hz), 7.60 (d, 1 H, J = 8 Hz). Anal. Calc. for C10H12IN●C2H2O4: C 39.68; H 3.88; N 3.85.
Found: C 49.68, H 5.68, N 3.57.
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